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Chapter 1. Introduction
1.1 Overview
Cystic Fibrosis (CF) is an inherited genetic disease typically causing severe damage to
the lungs and digestive system [1]. It has been recognized as the most common life-threatening
disease in the Caucasian population [2][3]. There are at least 30,000 registered patients living in
the United States and approximately between 70,000 and 100,000 cases all over the world [4][5].
In United States, CF occurs at an incidence of about 1 in 3,400 to 4,000 newborns, and around
1,000 new cases are diagnosed each year [2][6]. CF is also found in other ethnicities, but it is
difficult to state an accurate figure worldwide because people with CF in countries with less
developed health care systems not always receive proper diagnosis. Although the newborn
screening and the disease treatments have been enormously improved in the past decades, the life
expectancy of CF patients is still around mid- to late 30s to 40s [2][3].
Genetically, CF is caused by the mutation of cystic fibrosis transmembrane conductance
regulator (CFTR), which is a cAMP-regulated chloride (Cl-) and bicarbonate ion channel on the
surfaces of epithelial cells, especially those of the respiratory and gastrointestinal tracts [7][8].
Since the CFTR gene was discovered in 1989, more than 1,950 mutations have been identified
[7]. Among them, only around 200 have been demonstrated to be disease (CF) liable [8]. There
are two classification systems for CF mutations, one based on clinical consequences, and the
other based on CFTR structure-function defects [9]. Class I mutation affects protein production,
which include premature stop codons and cause mRNA degradation [9][10]. Class II mutation
causes protein misfolding and the retention at the endoplasmic reticulum (ER) membrane [9][10].
The consequent endosomal degradation prevents the functional protein reaching the apical cell
surface. Thus Class II mutation is defined as protein traffic defect. Class III mutation blocks the
9

regulation of the CFTR due to impaired channel gating function [9-11]. Class IV to VI are
responsible to different decreased protein functionality, which usually result less severe disease,
with comparison to the symptoms caused by Class I to III [9]. Finally, Class VII is characterized
as rescuable mutation because of the large deletion segmentation, which cannot be
pharmacological rescued [9][10]. The most frequent mutation, F508del, which is present in
around 85% patients worldwide, belongs to Class II mutation [12].
The dysfunction of CFTR causes a lack of conduction of chloride and bicarbonate across
the epithelial cells, which further results in an imbalance of other ions, pH and body fluids [9].
Although CF is a multi-organ disease, which can directly cause gastrointestinal abnormalities,
hepatic and pancreatic obstruction, even reproductive abnormalities, the most challenging
problem in the management of CF is the pulmonary disease, which is also mainly responsible for
symptoms, life quality burden and short life spans of patients [13].
CF related lung dysfunction is characterized as a decreased volume of airway surface
liquid (ASL), pulmonary mucus dehydration and subsequent impaired mucociliary clearance
(MCC) [14][15]. ASL consists of a more liquid-like periciliary layer (PCL) and a more gel-like
mucus layer [14]. These two layers coordinate to trap inhaled pathogens and particles, which are
subsequently transported towards the pharynx to be swallowed by cilia beat, together with
secreted mucus [14][16]. Sufficient PCL thickness and volume are critical to an effective
mucociliary clearance [17]. Typically, in the healthy population, mucus, mucociliary clearance,
in combination with the secreted antimicrobial factors, phagocytes and natural killer cells
constitutes the innate immune system for respiratory tract [15]. However, due to the defect of
CFTR, the secretion of coupled Cl- and sodium (Na+) ions is reduced in the lung of CF patients,
water cannot be “drawn” to the airway lumen as in normal airways [17]. Therefore, ASL is
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dehydrated, which leads to depleted volume of both PCL and mucus layer. The cilia beating is
impeded, which slows and even stops mucociliary clearance [17]. Meanwhile, as the
concentration of mucin increased in mucus layer, the rheology of airway mucus in CF patients is
also altered [18]. The viscosities and elasticities of CF mucus are significantly higher than
normal mucus [18][19]. Reduced bicarbonate secretion also changes the pH of ASL, and may
impact the innate immunity via the deactivation of antimicrobial peptides [13][15]. These
accumulative abnormalities in CF lung serve as perfect conditions for inhaled microorganism to
grow [20][21]. The consequent chronic infection and inflammation eventually leads to
pulmonary obstruction and respiratory failure, which is the most common cause for CF patient’s
mortality [5][22].
Without being able to eradicate inhaled microorganisms, patients with CF are susceptible
to respiratory infections since their childhood [2][13]. This has been also demonstrated by
pulmonary challenging newborn piglets with S. aureus [23]. Although there is no evidence of
inflammation in the airway of piglets with CF at first few hours after birth, they fail to eradicate
bacteria and are harbored with more bacteria than control piglets without this disease [23]. In
humans, lungs can be colonized with of a variety of bacteria and viruses, including Pseudomonas
aeruginosa, Staphylococcus aureus, Burkholderia cepacia complex and Haemophilus influenzae.
Interestingly, the species in bacteria community changes through the lifetime of CF
patients [4][24]. In their childhood, young patients usually acquire respiratory tract infection with
Haemophilus influenzae and S. aureus, resulting in bronchiectasis from the inflammatory
response [24]. As the disease progresses, patients become susceptible to a range of gramnegative bacteria, which are typically only associated with hosts who are immunocompromised
but not healthy people [24]. P. aeruginosa, which is a facultative anaerobic and opportunistic
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pathogen, is the most predominate species found in pulmonary infection related to CF [20][25].
This can be explained by a successful adaption to host defense [25][26]. The transmission of
microorganisms among CF patients was also observed in the past decades, including P.
aeruginosa and methicillin-resistant S. aureus (MRSA) [4][24]. Due to the poor clinical
outcomes associated with the infection causing by these species, the cross-infection has also
become a problematic issue, which requires substantial effort to resolve for many CF centers [4].
Chronic lung infections in CF patients with P. aeruginosa always involve formation of
biofilms, which is the most important adaptive mechanism against host defense and antibiotic
therapy [26][27]. P. aeruginosa is also one of the most extensively studies biofilm forming
microorganism. The stages of biofilm development are shown in Figure 1.1 [28]. Bacterial
biofilms are condensed microbial aggregates [25][26]. Planktonic cells are capable of forming
multicellular communities in organized structures attached to surfaces, in response to
environmental signals [25]. Bacteria in biofilms are surrounded by a self-produced hydrated
matrix called the extracellular polymeric substance (EPS) [29-31]. EPS is mainly composed of
polysaccharides, proteins, extracellular DNA (eDNA), lipids and large amount of water,
providing a stable microenvironment for bacterial proliferation [30][31]. Aided by the EPS,
bacterial biofilms develop their own specific antibiotic resistance mechanisms beyond those
traditionally observed in planktonic bacteria, such as modified enzymes, upregulated efflux
pumps and target mutation [27][29]. Proteins in EPS serving as enzymes can degrade the
structural components of EPS to release the planktonic bacteria back into environment, initiating
another life cycle of bacterial biofilm formation [27][28]. The eDNA in EPS is responsible for
genetic information exchange among bacteria in biofilms [32]. In the treatment of biofilm related
infections, the anionic polysaccharides and other biopolymers in the EPS can retard the
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penetration of antibiotics, even failing to reach the bacteria embedded in the deep layer of
biofilms, particularly those that can be protonated under conditions existing in the biofilm
[31][33]. For example, aminoglycosides, such as tobramycin, gentamicin and amikacin, which
have multiple primary amine groups, are easy to get protonated and bind to matrix components
in biofilm [33][34]. The slow penetration through EPS also provides greater opportunity for
enzymes to inactivate antibiotics, further attenuating overall drug concentration, which may lead
to an adaptive resistance within the biofilm [27][28]. The other mechanism causing antibiotics
treatment failure is the altered metabolism pattern in the biofilm. Some subpopulations of
bacteria in the inner layer of biofilm slow their metabolic activity to adapt to the low oxygen and
poor nutrient supply environment [35][36]. These bacteria response poorly to the antibiotics such
as beta-lactams and aminoglycosides, which efficiently target on actively dividing or growing
bacteria [35][36].

Figure 1.1 Development of a biofilm. At stage 1 the bacteria attach reversibly to a solid surface.
At stage 2 they are attached irreversibly to the surface and they lose motility. This step is mainly
mediated by the EPS. In the 3rd stage, the development of biofilm architecture is observed,
suggesting the early maturation of biofilm. In stage 4 the maturation is completed, and the
biofilm exhibits a complex and stable structure. In stage 5 single planktonic cells (black bacteria
13

in image) acquire mobility again, readily to detach from the dispersed biofilm and can start new
microcolonies somewhere else. This biofilm development step is also called dispersion stage.
In CF patients, bacterial biofilms are embedded in thick and sticky pulmonary mucus and
not in direct contact with the airway epithelial layer as seen in the cross-section Figure 1.2 [32].
Such viscous mucus represents as an additional physical barrier preventing drug and drug
particles from reaching the bacterial biofilm [32]. There have been many studies showing that
aminoglycosides can bind to mucin, which is the main component of pulmonary mucus
[32][37][38]. These combined barriers represent a formidable challenge preventing the delivery
of effective drug doses reaching the bacterial biofilms, resulting in incomplete bacteria kill and
further resistance mechanisms can thus generate a cycle of increased overall resistance to the few
antimicrobial agents available to treat the disease. Therefore, the development of new treatment
strategies capable of improving effectiveness of existing antibiotics in treating bacterial infection

in biofilms in CF represent an unmet clinical need.
Figure 1.2 P. aeruginosa is localized in intraluminal material of freshly excised CF airways
and binds to mucus. Thin section of an obstructed CF bronchus, stained with hematoxalin/eosin.
Note the absence of P. aeruginosa on epithelial surface (black arrow) and presence of P.
aeruginosa macrocolonies within intraluminal material (white arrows). Blue gap is an artifact
due to fixation.
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1.2 Treatment of CF infection
As mentioned earlier, CF is a disease most gravely affecting the lungs. Pulmonary
complications caused by bacterial infections and subsequent impaired lung function contribute to
the poor prognosis in CF patients [13]. The main goal in standard of care in the treatment of
patients with pulmonary complications from CF include enhancing of the mucociliary clearance
(MCC), preventing of bacterial infections, suppressing chronic colonization, and reliving the
inflammatory stress in airway [13]. The ability to local deliver treatment to the lungs via oral
inhalation has many important implications, including decrease in off-target toxicity resulting
with systemic administration [39][40].

However, as described above, there are many

physiological barriers in diseased CF lungs that challenges the effective delivery of drugs upon
pulmonary administration.
In order to clear the thick mucus in lung and restore the MCC functionality, inhaled
mucolytics (e.g., recombinant human DNase, Pulmozyme®, mannitol) are used in CF patients
[41][42]. Hypertonic saline is also inhaled to rehydrate mucus, usually in combination with a
bronchodilator to further help patient cough out viscous mucus via a physiotherapy [41-43].
As the major pathogen in adult patients is P. aeruginosa [24]. Prevention of P.
aeruginosa infections is mandatory in CF disease management [44]. An early antibiotic
treatment usually consists of inhaled antibiotics such as tobramycin and colistin, oral and
intravenous antibiotics such as ciprofloxacin and combinations of aminoglycosides and betalactams if there is any exacerbation happens [45][46]. However, though high doses and longterm administration of inhaled and intravenous antibiotics like tobramycin, aztreonam, and
colistin in combination with mucolytics and physiotherapy can suppress the infection
temporarily, once the chronic colonization with P. aeruginosa is established by forming biofilm,
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these chronic infections show increased tolerance to the innate and adaptive immune system,
phagocytosis and the administered antibiotics [35].
Inhaled antibiotics are designed to maximize drug delivery directly to the infection site
and to limit systemic side effects [45]. Most inhaled antibiotics to treat CF available in the
market are formulated in solutions or suspensions and delivered by nebulization [45]. For
example, Tobramycin (TOBI®) and aztreonam (CAYSTON®) nebulization solutions are the
two clinically approved inhaled antibiotics for treating chronic lung infections caused by P.
aeruginosa [45][47]. In US, there are 69% CF patients with colonization of P. aeruginosa
currently under tobramycin inhalers [45]. However, prolonged administration times (15-20 min
for nebulization and up to 1h including devices preparation and maintenance) and repeated
dosing (both formulations need 2~3 doses daily in an alternating month use) can be challenging
for CF patients [45]. Moreover, it is reported that in about 90% of CF patients, the concentration
of antibiotics in sputum needs to achieve at least 25 times of MIC to effectively kill bacteria [24].
Thus, the inhaled antibiotics usually requires a relatively high dose to show therapeutic effect.
The encapsulating antibiotics in nanocarriers represent a promising formulation strategy
in order to help address this unmet need in the treatment of persistent bacterial biofilm infections
in CF patents, as we try to overcome the drug resistance mechanisms caused by mucus and
biofilm formation as discussed earlier [48]. These nanostructured carriers can be prepared with
various compositions and structures, including biodegradable polymers and lipid-based systems
[49][50]. Similar to traditional antibiotics, nanocarrier-based antibiotics can also be administered
as inhalation aerosols, thus minimizing systemic exposure and related side effects [51-53]. With
careful design, drug-loaded nanocarriers can potentially offer a better opportunity for drugs to
penetrate into the biofilm compared to the free drug due to their surface characteristics that may
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minimize drug-ECM (extracellular matrix)/mucus protein interactions [49]. In addition, by
manipulating the surface properties of nanocarriers, the antibiotics can be protected from
enzymatic hydrolysis until they reach the site of action, and further, it offers an opportunity for
controlled release of the active antimicrobial molecule [54][55]. A sustained release could also
contribute to prolonged dosing interval and better patient compliance [54]. Nanocarrier-based
systems have been shown to improve pharmacokinetics (PK) and lung tissue biodistribution
[56][57]. Moreover, nanoscale carriers are generally not recognized as foreign entities [58].
In the past two decades, the concept of liposome and polymer-based nano-antibiotics
have been extensively developed [48]. The antimicrobial efficacy of liposomal antibiotics,
especially against P. aeruginosa, has been shown in numerous in vivo studies to be clearly
superior to that of the free antibiotics in many circumstances, despite the fact that liposomal
antibiotics do not necessarily show better efficacy than the free antibiotics in overcoming the
mucus barrier in vitro [59][60]. The surface charge of nanoparticles is always a critical factor as
is their size [61]. Although neutrally charged liposomal antibiotics have been shown to be able to
sufficiently penetrate the mucus within the same timeframe as the sustained antibiotic release,
the distribution of liposomes in much may be inhibited to a certain extent [62][63]. Furthermore,
antibiotic leakage from the liposomes upon their interaction with mucus may take place due to
the limited physicochemical stability of liposomes in presence of various mucus compound
[64][65]. Several successful clinical studies have led to the development of liposomal antibiotics
including for oral inhalation [60][65][66]. Arikayce® (amikacin liposome inhalation suspension)
has been approved by FDA in 2018 for treatment of nontuberculous mycobacteria lung infection.
Lipoquin® (inhaled ciprofloxacin liposome) has completed phase III clinical trials in 2017 and
received FDA orphan drug designation in 2019. The superior antimicrobial efficacy of the
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liposomal antibiotics observed in clinical trials, where only once a day treatment is needed
compared to twice daily for the free drug can be attributed primarily to their prolonged retention
in the lungs and sustained antibiotic release, and not necessarily because of a demonstrated
ability to penetrate the mucus (or bacterial biofilm) to a better extent than free antibiotics.
Meanwhile, the other bottleneck that liposomal antibiotics faces is the large amount of antibiotics
lost during their preparation, storage, inhaled administration, and mucus interaction, which can
potentially derail broad clinical applications of liposomal antibiotics [65][66].
On the other hand, the formulation of nano-antibiotics in polymeric matrices does not
face the limited physicochemical stability issues seen in liposomal antibiotics [48]. Clinical
realization of polymeric nano-antibiotics is more challenging, however, due to their low
antibiotic loading and uncertain biocompatibility in the lung compared to lipid-based systems
[67]. Due to the low antibiotic loading, a large amount of polymeric material is needed to be
administered to achieve the therapeutic doses. Therefore, in order to minimize the cytotoxicity of
polymeric nanoparticles in the lungs becomes a crucial issue. Although it has been found that
conjugating polymeric nanoparticles with PEG can reduce the cytotoxicity of polymeric
nanoantibiotics in the lungs, high PEG density can also decrease the targeting efficiency and
reduce the interaction between nanoparticles and bacteria, potentially resulting in lower
therapeutic effects [68]. To overcome mucus barrier, another important consideration regarding
the use of nanocarriers for treating CF is their size [69]. The mucus has a porous structure made
of crosslinked mucin fiber and these pores typically fall in the range of ≈200–500 nm in
chronically infected lungs. Therefore, particles with a size lager than 500 nm may be “trapped”
in mucus layer [2].

18

There are clear advantages and challenges in the development of nanocarrier-based
antibiotic formulations. Liposomal formulations may improve lung PK of antibiotics, but loss of
API during stock and administration process is an issue due to limited physicochemical stability.
For polymer-based nanoparticles, relatively low drug loading is an issue, which is usually caused
by incompatibility of hydrophilic API and the hydrophobic nature of polymeric carriers. Toxicity
is another concern when considering of such polymeric matrices. For both liposomes and
polymeric nanoparticles with sizes typically around 80~100 nm, there are important size
considerations with respect to mucus mesh size and their ability to diffuse freely in the biofilm
[69]. Taking all those aspects in consideration, dendrimers emerge as potential nanocarrier of
particular interest given their small size (usually under 10 nm), highest payload capacity by
weight material from all nanocarrier systems, and availability of a large number of surface
groups which can be functionalized with both therapeutic molecules and ligands via tunable
chemistry bonds allowing for the design of drug carriers that can minimize non-bonded
interactions with both ECM in biofilm and mucus environment [70-72]. Dendrimers are at the
center of the work discussed in this dissertation.

1.3 Hypothesis and Objectives
We hypothesize that the conjugation of tobramycin to dendrimers via a liable bond and
proper surface modification of the resulting conjugates will lead to enhanced bacterial biofilm
kill. The rationale behind this hypothesis is based on the expectation that conjugation of the drug
to a PEGylated dendrimer will (i) prevent non-bonded interactions between protonated amines in
tobramycin (Tobra) as PEG can shield those charges (we can assess this by measuring the
surface charge of the resulting conjugates); (ii) leading to a

greater penetration/improve

distribution of the carriers throughout the mucus and biofilm (we can assess this with the proper
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design of dendrimer conjugates and imaging); and (iii) as a consequence, will lead to improved
bacterial cell kill (we can assess by assaying the impact of treatment on bacterial biofilms).The
long term goal of our work is to develop improved oral inhaled antibiotic formulations that will
help improve the life expectancy and quality of life for CF patients, thus helping meet this
important clinical need in the treatment of CF.
We expect to achieve the objectives of this project by pursuing the following three aims:
Aim #01. Synthesize and characterize biodegradable polyester dendrimertobramycin conjugates with varying surface characteristics and prepare their aerosol
formulations. We hypothesize that the conjugation of Tobra to dendrimer and further
modification of surface groups of dendrimers with PEG will lead to the development of
conjugates with enhanced mucus and biofilm distribution/penetration ability. In Chapter 2,
generation 4, polyester dendrimer-tobramycin-PEG (G4OH-Tobra-PEG) conjugates and nonPEGylated controls (G4OH-Tobra) were synthesized. Tobra was conjugated to dendrimer via a
hydrolysable ester bond, allowing enzymatic or pH dependent hydrolysis in the bacterial
biofilms. Conjugates were characterized using 1H-NMR, MALDI-TOF, light scattering (DLS)
for size and surface charge. In future work in the lab, those nanocarries will be formulated into
microparticles in lactose matrix and prepared in orally inhaled dry powder form as we have done
in the past for other dendrimer-drug conjugates [73]. These nano-antibiotics have been disclosed
to VCU.
Aim #02. Determine the activity of dendrimer-tobramycin conjugates against nonmucoid and mucoid P. aeruginosa biofilms in vitro. We hypothesize that the conjugation of
Tobra to dendrimer, and further surface groups modification will lead to the development of
conjugates that are capable of modulating the interaction between Tobramycin and the mucus
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layer and EPS, allowing a potential increase of local concentration of antibiotic throughout the
bacterial biofilm and thus their cell kill. We tested the antimicrobial activity of dendrimertobramycin conjugates against planktonic bacteria and antibiofilm activity in static biofilms. The
results were correlated with the ability of the conjugates to distribute in the biofilm model grown
under flow, as measured by Fluorescence Recovery After Photobleaching (FRAP). (To establish
a more realistic environment to assess the behavior of the conjugates, some preliminary data of a
co-culture model (bacterial and mammalian cells) was also attempted.)
Aim #03. Review in vitro dissolution methodologies with focus on device set-up and
the composition of mimicking biorelevant fluids. As our dendrimer-based antibiotics are
designed to be inhaled by CF patients in the future, we are interested in the fate of aerosol
particles after inhalation. The factors affecting the subsequent dissolution and absorption process
under biopharmaceutical context is presented in Chapter 3, in the form of a review article. The
most recent in vitro dissolution methodologies are summarized along with whatever limited
regulatory considerations exist for dissolution of orally inhaled drug products (OIDP). This
chapter was also motivated by the semester long internship at Aurobindo, where I needed to
understand all those aspects of dissolution testing of OIDPs in the context of bioequivalence of
generic drugs and quality assurance during formulation development.

1.4 Innovation
In this work, we propose to use generation four polyester dendrimer (G4OH) as
nanocarrier for antibiotics for the treatment of CF related biofilms. With 48 surface groups,
G4OH provides for the opportunity to achieve high drug loading, and the possibility of surface
modifications to modulate the interaction between dendrimer conjugate and the surrounding
physiological environment. The stability of formulation is also improved since API will be
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conjugated to dendrimer via chemical bonds that will degrade upon triggers found in the biofilm
environment. Ultimately, we aim to develop an orally inhaled therapy for the treatment of
bacterial infection in CF, that leads to improved bacterial biofilm kill, prolonged dosing interval
and better patient compliance compared to current treatment strategies with free drugs or drugs
in liposomal form.
We are the first group to propose the use of polyester dendrimers as a platform for the
delivery of aminoglycosides in the context of CF. Although PAMAM dendrimers have been
extensively studied as nanocarriers in drug delivery, including gene therapy and anticancer
chemotherapy, safety issues are of concern due to potential toxicity associated with such carriers.
Contrary to PAMAM dendrimers, OH-terminated polyester dendrimers are biodegradable under
physiological conditions, which offers an opportunity to achieve reduced toxicity profile.
We are also the first group to work on the conjugation of aminoglycoside antibiotics with
dendrimers (in general and also for polyesters), and to propose a dry powder formulation (DPI)
for the oral inhalation delivery of these nanomedicines. As we combine nano-antibiotics and
DPIs, we have a higher chance to decrease dosing frequency, reduce potential side effects,
improve patient compliance and further contribute to the quality of life of CF patients.
Lastly, the common approaches to evaluate the efficacy of new treatments for CF are
usually either employing bacterial biofilm model alone or using patients’ sputum/artificial mucus.
These approaches, however, are limited as they do not consider the interaction between bacterial
biofilm and host mammalian cells. Although there are a few studies establishing bacteria-host
cell co-culture system, due to severe acute toxicity posed on mammalian cells from bacteria,
these systems cannot sustain long enough for bacteria to form mature biofilm. In addition, the
focus of those studies has been to investigate how bacteria biofilm grow in such conditions. We
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present some preliminary data towards the development of a novel long-lasting co-culture model,
in which mature bacterial biofilms are formed on polarized airway epithelial cells, mimicking
typical chronic infections in CF patients. Once fully developed, the model can be used as a more
robust drug screening strategy, including for our nano-antibiotics.
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Chapter 2. Biodegradable Dendrimer Nanocarriers for the Delivery of
Tobramycin to Pseudomonas Aeruginosa Biofilms
Abstract
Pseudomonas aeruginosa (PA) is the predominant pathogen in chronic lung infections of
cystic fibrosis (CF) patients. The most important mechanism of adaptation of PA to host defense
and antibiotic treatment is the formation of biofilms within the mucus layer covering the lung
bronchi. The effectiveness of antibiotics such as aminoglycosides is significantly attenuated by
their limited penetration through thick mucus and embedded biofilm matrix in patients’ lung.
Inhaled tobramycin (Tobra), which is the most commonly used antibiotics in the treatment of PA
infections for CF patients, is usually found to be in very high concentration (>25 folds of MIC)
in patients’ lung, and yet still cannot prevent CF pulmonary exacerbation. The purpose of this
study was to develop biodegradable dendrimer nanocarriers (DNCs) with appropriate
physicochemical characteristics that would promote carrier diffusion/penetration through PA
biofilms and pulmonary mucus. We investigated the effect of surface charge of DNCs on their
pentation and diffusion. The positive charge of amine-modified, fluorescently-tagged (FITC),
generation 4 polyester dendrimers (G4OH-(NH2-FITC)) led to slower mobility in PA biofilms
and model mucus layer compared to their PEG 1000Da-modified negatively charged analogs
(G4OH-(NH2-FITC)-(PEG)) as measured by fluorescence recovery after photobleaching (FRAP).
The enhanced penetration of the PEGylated analogs was attributed to the fact that PEG can act to
modulate the interactions between DNCs and the negatively charged biopolymers in biofilm and
mucus matrix upon shielding the surface of the otherwise positively charged carrier.

The

effectiveness of Tobra-dendrimer conjugates either modified with PEG (neutral, G4OH-(Tobra)(PEG)) and non-PEGylated (positive charge, G4OH-(Tobra)) was assessed in planktonic and
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biofilms of non-mucoid (PAO1) and mucoid (FRD1) PA strains. The minimum inhibitory
concentration (MIC) of Tobra hydrolyzed from the DNCs was of similar magnitude as to free
Tobra, indicating that the conjugation and release of Tobra leads to bioactive drug as the nonreleased analog and G4OH themselves have MIC >> then free drug. By contrast, in an
established PA biofilm model, PEGylated dendrimer-drug conjugates demonstrated a
significantly stronger bioactivity in eliminating biomass at relatively higher concentration (8, 16
µg/mL) compared to free Tobra and the positively charged G4OH-(Tobra) in mucoid PA strain.
Our results demonstrate a correlation between the surface characteristics of the dendrimer
nanocarriers and their ability to efficiently penetrate PA biofilms, and also that those negatively
charged dendrimer nanocarriers can lead to enhanced efficacy in reducing biofilm in relevant
mucoid PA strains. Biodegradable dendrimer nanocarriers with appropriate design of surface
chemistry can thus be a promising approach to overcome the antibiotic resistance in the
treatment of biofilms in CF infections.

2.1 Introduction
Cystic Fibrosis (CF) is an inherited, life-limiting genetic disease, usually characterized
with thick and sticky mucus in several organs, particularly in the lung 0. This disease is caused
by mutation of cystic fibrosis transmembrane conductance regulator (CFTR), leading to
pulmonary mucus dehydration and impaired mucociliary clearance [44][74]. Being unable to
clear inhaled microorganisms, patients with CF therefore become more susceptible to respiratory
infections [12]. The lungs of CF patients are colonized with of a variety of bacteria and viruses.
Among them, Pseudomonas aeruginosa (PA) eventually becomes the dominant species due to
the successful adaption to host defense [21][23]. The median life expectancy of CF patients is
late 30s and can reach to early 40s in developed countries [2][3]. The pulmonary diseases caused
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by PA infection are mainly responsible for symptoms, life quality burden and short life spans of
CF patients [12].
Chronic lung infections with PA always involve formation of bacterial biofilms, which is
the most important adaptive mechanism against host defense and antibiotic therapy [21][75].
Planktonic cells can gather and form a multicellular, complex community in organized structure
called a biofilm. Bacteria in biofilms are embedded in a self-produced hydrated matrix called the
extracellular polymeric substance (EPS) [20][21][26]. Due to the presence of EPS, impaired drug
penetration, low active molecule accessibility and drug induced environmental stress response all
contribute to biofilm resistance to therapy [21][20][76][77]. The highly viscous mucus where the
biofilm is harbored also acts as a barrier for achieving therapeutic concentration of antibiotics in
the biofilm [32]. Thus, the biofilms in CF are extremely difficult to eradicate. Despite the
aggressive use of antibiotics, the concentration of antibiotics to successfully inhibit biofilmgrowing bacteria can still be up to 100-fold compared to minimum inhibitory concentration
(MIC) of bacteria in planktonic phase [20].
Inhaled antibiotics are designed to maximize drug delivery directly to the infection site
and to limit systemic side effects [78]. In the US, ca. 69% of CF patients with colonization of PA
currently use TOBI®, an inhaled form of tobramycin (Tobra), to treat chronic infection,
including in nebulizer and dry powder inhaler (DPI) dosage forms [78][79]. Tobra is a broadspectrum aminoglycoside, which is particularly used to treat Gram-negative infections [80].
However, as anionic polysaccharides and other biopolymers such as eDNA, mucin carries
overall negative charge and can thus bind to Tobra via their protonatable functional groups
(mostly -NH2). In a mucus encased biofilm environment, therefore, the efficiency of Tobra is
significantly hindered as it is not capable of efficiently penetrating through both mucus and the
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ECM of bacterial biofilm [21][24][32]. Innovative strategies that lead to high local concentration
of therapeutics into the site of infection are thus needed to enhanced therapies of
aminoglycosides such as Tobra to CF patients.
Nanocarrier-based delivery system such as lipid-based and polymer-based nanocarriers
have been shown to be a promising strategy to overcome the antibiotic resistance associated with
chronic infections in CF patients [77]. Nanocarrier-based systems have been shown to improve
the pharmacokinetics (PK), biodistribution and exert sustained drug release, which may lead to
prolonged dosing intervals and improved patient compliance. Importantly, the nanocarriers and
their surface modification allow for importunities to modulate the interaction between drug
molecules and the physiological environment, including extracellular barriers such as mucus and
ECM, which can be used to improved drug penetration in biofilms and thus improve therapeutic
efficacy. For instance, Arikayce® (amikacin liposome inhalation suspension) has been approved
by FDA in 2018 for treatment of nontuberculous mycobacteria lung infection. However,
antibiotic liposomal formulations of antibiotics have some drawbacks, such as loss of API during
stock and administration process due to limited physicochemical stability. It is unclear the ability
of such formulations to penetrate through the much layer and ECM.

For polymer-based

nanoparticles, relatively low drug loading may also be an issue, which is usually caused by
incompatibility of hydrophilic drug and the hydrophobic nature of polymeric carriers. Compared
to liposomes and polymeric nanoparticles, dendrimer are nanocarrier with unique characteristics
including their small size (a few nm in diameter), the availability of a large number of surface
groups which can be functionalized with therapeutic molecule and ligands via tunable chemistry
bonds that allows for both delivery of high payloads and to modulate the interactions with the
physiological environment.
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Based on the challenges and opportunities described earlier, our goal was to develop
polyester dendrimer nanocarriers with surface characteristics that leads to enhanced penetration
in both mucus and PA biofilm, and the corresponding Tobra-conjugates, so as to assess their
potential in the treatment of bacterial biofilms. In contrast to widely used poly(amidoamine)
(PAMAM) dendrimers, polyester dendrimers are prepared with biodegradable building blocks,
thus offering an opportunity to mitigate toxicity issues associated with PAMAMs [81][82]. We
hypothesized that the surface modification of dendrimers with PEG will screen the interaction
between positively charged surface groups of the drug payload (in this case from protonated
amines in Tobra) and the overall negatively charged biopolymers in mucus/ECM will, thus
leading to lead to enhanced penetration in mucus and biofilm, and thus improved ability to
reduce biofilm burden.
In this work, we synthesized and characterized dendrimer-Tobra conjugates and their
analogs modified with dense PEG. The antimicrobial activity of synthesized dendrimer drug
conjugates, as well as their corresponding hydrolyzed products, was evaluated in planktonic PA
and reported minimum inhibitory concentration (MIC). Antibiofilm studies were conducted in
static and flow-formed PA biofilm assays, including biomass and cell viability evaluation.
Besides dendrimer drug conjugates, we also synthesized a model dendrimer system without
Tobra but possessing the similar surface properties and a tracer (FITC). This model was used to
assess the penetration and diffusion of positively charged and PEGylated dendrimer through
mucoid and non-mucoid PA biofilms and synthetic mucus using fluorescence recovery after
photobleaching (FRAP) and confocal microscopy. The novelty in this work stems from the fact
that this represents the first work to demonstrate the conjugation of aminoglycoside antibiotics
with polyester dendrimers, and the demonstration of their potential in eradicating PA biofilms.
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2.2 Materials and Methods
2.2.1 Synthesis and Characterization of Dendrimer Conjugates.
2.2.1.1 Materials.
Generation 4, Bis-MPA hydroxyl dendrimer, TMP core (G4TMP-OH), was purchased from
Polymer Factory (Stockholm, Sweden) with molecular weight (MW) of 5357.4 Da. Di-tert-butyl
decarbonate ((Boc)2O), 6-(Boc-amino)hexanoic acid, triethylamine (TEA) and hydrogen chloride
(HCl), 4M in 1,4-dioxane were purchased from Alfa Aesar (Haverhill, MA, USA). Ammonium
Hydroxide was purchased from EMD Milipore (Billerica, MA). Pyridine (anhydrous grade),
succinic

anhydride,

ethylcarbodiimide

4-(dimethylamino)pyridine
hydrochloride

(EDC),

(DMAP),

N-(3-dimethylaminopropyl)-N-

N-hydroxysuccinimide

(NHS),

dicyclohexylcarbodiimide (DCC), diisopropylethylamine (DIPEA), poly(ethylene glycol)
monomethyl ether (mPEG, Mn 1,000 Da (1KDa)) and 2,5-dihydroxybenzoic acid (2,5-DHB)
were purchased from Sigma-Aldrich (St Louis, MO, USA). Tobramycin (Tobra),
dichloromethane (DCM), dimethylformamide (DMF, anhydrous grade), dimethyl sulfoxide
(DMSO), and diethyl ether (Et2O) were purchased from VWR International (Radnor, PA, USA).
Fluorescein isothiocyanate (FITC) was purchased from Thermo Fischer Scientific (Rockford, IL,
USA). Spectra/Por regenerated cellulose (RC) membrane dialysis tubing (MWCO=1000 Da and
8000 Da) was purchased from Spectrum Laboratories, Inc. (Rancho Dominguez, CA, USA).
Deuterated dimethylsulfoxide (DMSO-d6), methanol (CD3OD) and deuterium oxide (D2O) were
bought from Cambridge Isotope Laboratories (Tewksbury, MA, USA).
2.2.1.2 Synthesis of G4OH-(NH2-FITC) and PEGylated analog
Synthesis of mPEG (1KDa) anhydride
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mPEG (MW=1KDa, 5.12 g, 5.12 mmol) was dissolved in 5 mL DCM in the presence of
DMAP (125.2 mg, 1.02 mmol) and 1.24 mL pyridine (15.4 mmol). The mixture was cooled
down to 0˚C and succinic anhydride (1.02 g, 10.24 mmol) was then added. The reaction was
stirred overnight. The reaction mixture was then diluted to 60 mL with DCM and washed with
10% aqueous NaHSO4 (20 mL×3 times). The organic phase was dried over anhydrous
magnesium sulfate and precipitated twice with cold diethyl ether. The waxy solid product was
collected as mPEG-COOH. Synthesized mPEG-COOH (2.4 g, 2.19 mmol) was dissolved in
DCM (8 mL) and cooled to 0°C. DCC (225.9 mg, 1.09 mmol) was dissolved in 2 mL DCM and
added to the mixture dropwise. The reaction was stirred vigorously overnight. The crude reaction
mixture was filtered through a medium porosity glass filter and the filtrate was collected and
evaporated to dryness. The resulting viscous liquid was diluted with 3 mL DCM and precipitated
twice in cold ethyl ether (100 mL). The resulting white waxy pellet was mPEG anhydride.
Surface modification of G4OH dendrimer
G4OH (81 mg, 15.13 µmol) was mixed with (6-Boc-amino) hexanoic acid (46.40 mg,
199.7 µmol) and DMAP (36.6 mg, 294 µmol) in 5 ml anhydrous DMF. The system was stirred at
room temperature for 10 min, and then EDC (57.43 mg, 294 µmol) suspended in 2 ml DMF was
added dropwise to the above mixture. The reaction was continuously stirred at room temperature
overnight. The product was evaporated under high vacuum and then diluted with 80 ml DCM.
The solution was washed with 10% NaHCO3 (10 mL×3 times) and 10% HCl (10 mL×3 times)
until TLC showed no impurities. Then the organic phase was dried over anhydrous magnesium
sulfate and evaporated under reduced pressure. The resulting G4OH-linker (30 mg) was
dissolved in 5 ml 4M HCl in dioxane and stirred for 30 min at room temperature. The mixture
was then dried with blowing N2 gas and redissolved with 2 ml DMSO. The solution was purified
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with a dialysis membrane (MWCO=1kDa) against DMSO for 12h and then DI water for 24h.
The product (G4OH-NH2) was frozen and lyophilized overnight to dry.
Synthesis of G4OH-(NH2-FITC)
G4OH-NH2 (14 mg, 2.24 µmol) was reacted with FITC (2.6 mg, 6.7 µmol) in 2 ml
DMSO with TEA (1.6 µL, 11.2 µmol). The reaction was stirred at room temperature overnight.
The crude product was dialyzed against DMSO (MWCO=1kDa) for 24h and DI water for 24h
subsequently. Characterization of all the intermediate and final conjugate compounds were
determined by proton nuclear magnetic resonance (1H NMR) and matrix-assisted laser
desorption/ ionization-time-of-flight mass spectrometry (MALDI-ToF MS) for chemical
composition and molecular weight. Light Scattering (LS, Malvern Zetasizer) was used to obtain
the hydrodynamic diameter (HD) and zeta potential (ζ) of the conjugates.
Synthesis of G4OH-(NH2-FITC)-(PEG)
Previously synthesized G4OH-(NHBoc) (10 mg, 1.4 µmol) was mixed with mPEG
anhydride (121.9 mg, 55.9 µmol), DMAP (0.7 mg, 5.6 µmol) and pyridine (7 µl, 83.8 µmol)
dissolved in 4 ml anhydrous DCM. The reaction was kept at 0˚C for 30 min and stirred at room
temperature overnight. Then the mixture was evaporated with vacuum. The residue was
dissolved in DMSO and purified with dialysis membrane (MWCO=8kDa) against DMSO. The
resulting G4OH-(NHBoc)-(PEG) was dissolved in 3 ml 4M HCl in dioxane and stirred for 30
min at room temperature. The mixture was then dried with blowing N 2 gas and redissolved with
2 ml DMSO. The solution was purified with dialysis membrane (MWCO=1kDa) against DMSO
for 24h and followed by DI water for another 24h. G4OH-(NH2)-(PEG) (9 mg, 0.34 µmol) was
reacted with FITC (0.5 mg, 1.3 µmol) in 2 ml DMSO with TEA (1 µl, 7.2 µmol). The reaction
was stirred at room temperature overnight. The crude product was dialyzed against DMSO

31

(MWCO=1kDa) following by DI water for 24h. The purified product was frozen and lyophilized
dry. The resulting G4OH-(NH2-FITC)-(PEG) conjugate was characterized with 1H NMR,
MALDI-ToF and LS.
2.2.1.3 Synthesis of G4OH-Tobra and PEGylated analog
Synthesis of Boc-protected Tobra succinate (TB-SA)
Tobra (701.93 mg, 1.5 mmol) was mixed with 2.76 mL (12 mmol) di-tert-butyl
decarbonate in 15 mL solvent (DMF:H2O = 8:2). The mixture was stirred at 60°C for 5h until
becoming clear. The solution was then concentrated to 1~2 mL at reduced pressure. Ammonium
hydroxide aqueous solution was added (~ 4-5 drops) to precipitate the product. The mixture was
diluted with 40~50 mL DI water, centrifuged at 4000 rpm for 10 min, and the pellet was washed
by DI water thrice. After washing, the precipitate (Tobra-Boc) was lyophilized overnight to dry.
Tobra-Boc (200mg, 0.21 mmol) was dissolved in 3 mL DMF and then reacted overnight with
41.4 mg succinic anhydride (0.414 mmol) in presence of 144.3 μL DIPEA (0.83 mmol). The
solution was concentrated to around 1 mL under reduced pressure and then diluted with 30 mL
anhydrous ethyl acetate. The ethyl acetate was extracted with saturated sodium bicarbonate
(NaHCO3) aqueous solution (10 ml×3 times). The organic layer was dried over anhydrous
magnesium sulfate and then evaporated under reduced pressure. The resulting product was Bocprotect tobramycin succinate (TB-SA).
Synthesis of G4OH-(Tobra)
G4OH-NH2 (26.5 mg, 3.6 µmol) was mixed with 126.2 mg TB-SA (118.2 µmol) and
21.1 mg NHS (177 µmol) in 5 mL anhydrous DMSO, stirring at RT for 10 min. Then 35 mg
EDC (177 µmol) was added dropwise. The reaction was stirred for 48h at room temperature. The
mixture was purified with a dialysis membrane (MWCO = 8kDa) against DMSO for 24h and
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then against DI water for another 24h. Then the product (G4OH-(TB)) was frozen and
lyophilized dry. The Boc protecting groups on conjugated Tobra were removed by reacting with
4M HCl in dioxane for 30 min and dioxane was evaporated. The final product was redissolved
with DMSO and dialyzed to purify (MWCO = 8kDa) against DMSO and then DI water each for
24h. The pure G4OH-(Tobra) conjugate was obtained after lyophilization. The purified product
was characterized by 1H NMR, MALDI-ToF and LS.
Synthesis of G4OH-(Tobra)-(PEG)
Previously synthesized G4OH-(TB) (57.26 mg, 3.6 µmol) was reacted with mPEG
anhydride (498.5 mg, 0.23 mmol) in 5 mL DMF with pyridine (27.6 µL, 0.34 mmol) and catalyst
DMAP (2.8 mg, 23 µmol). The mixture was stirred at room temperature for 48h. The crude
product was dialyzed against DMSO (MWCO = 8kDa) for 24h and lyophilized to dryness. HCl
4M in dioxane was added and reacted for 30 min to remove Boc protecting groups. Dioxane was
evaporated. The residue was then diluted with DMSO and dialyzed (MWCO = 8kDa) against
DMSO followed by dialysis in DI water. The final product (G4OH-(Tobra)-(PEG)) was
characterized by 1H NMR, MALDI-ToF and LS.
2.2.2 Bacteria Culture and Related Assays
2.2.2.1 Microorganisms and Materials
PA PAO1, FRD1 and FRD1 expressing GFP (established in Professor Dennis Ohman’s
laboratory at Virginia Commonwealth University). Luria Broth (LB broth) and agar were
purchased from VCU supply center. Bacteria were subcultured on LB agar for 24h at 37˚C then
grown in fresh LB broth overnight in a shaker at 225 rpm. Bacteria suspension was subsequently
diluted to desired CFU based on optical density (OD) value. Tobra, acetic acid and crystal violet
were obtained from VWR International (Radnor, PA, USA). Mucin from porcine stomach was
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purchased from Sigma-Aldrich (St Louis, MO, USA). Phosphate buffered saline (PBS, 1×, pH =
7.4) was prepared in our laboratories. Flat-bottom 96-well plates were purchased from Corning
(Corning, NY, USA).
2.2.2.2 Antimicrobial Activity of Dendrimer-Tobra Conjugates against Planktonic PA
To evaluate the antimicrobial activity against planktonic PA, we determined the
Minimum Inhibitory Concentration (MIC). Briefly, either PAO1 or FRD1 bacteria culture were
adjusted to 1×106 cfu/mL and 50 µL bacteria suspension was inoculated to 96-well plate and
grown overnight. All treatments were dissolved in 0.9% NaCl and serial dilutions were prepared.
A total of 50 µL of each treatment (for all concentrations) were added into the respective wells.
The microplates were incubated at 37˚C for 16-20h. MIC was determined as the lowest
concentration showing no visible signs of growth. All serial dilutions of dendrimer-Tobra
conjugates were prepared at Tobra equivalent concentration to free Tobra based on the
determined number of conjugated Tobra.
To investigate the bioactivity of Tobra conjugated to dendrimer, we applied basic
conditions to dendrimer-Tobra conjugates and their PEGylated analog leading to accelerated
release of Tobra. G4OH-Tobra, G4OH-Tobra-PEG and free Tobra were all diluted in PBS at
1024 µg/mL (Tobra equivalent concentration) as stock solutions. Each of 50 µL of 1 M NaOH
was added to 100 µL corresponding stock solutions and stirred at 37˚C for 24h. Subsequently,
the reaction was stopped by adding 50 µL of 1 M HCl and the pH was adjusted back to 7.4. All
hydrolyzed compounds were serially diluted to desired concentrations and the MIC was assessed
as described above.
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2.2.2.3 Penetration and Diffusion of FITC Labeled Dendrimer Conjugates in Synthetic
Mucus and PA Biofilm
Synthetic mucus was prepared according to the a method reported in the literature, with
slight modification [83]. A mucus buffer containing NaCl (5 mg/mL) and KCl (2.2 mg/mL) was
prepared and sterilized. Porcine mucin was mixed with buffer at a concentration of 40 mg/mL.
The mixture was vortexed and then shaken by a tube rotator overnight. The synthetic mucus was
stored at 4˚C. An aluminum chamber for the growth of biofilms under flow was designed and
manufactured as described in the, with some modifications [84]. The flow cell was assembled by
coverslips to the top and bottom of the chamber and sterilized [85]. After saturating the system
with fresh LB medium for at least 1h, 250 μL of bacteria suspension (diluted overnight culture
with OD600nm = 0.002) was injected to each channel (piercing the tubing) with a 30G needle.
After injection, the bacteria were left to adhere to the cover slip for 2 hrs in the absence of flow.
Flow was then resumed and the whole the system, including medium reservoir, kept at 37°C for
3~4 days until the biofilm was maturely formed. Before the penetration and diffusion experiment,
the biofilm was carefully washed by flowing PBS through the chamber. 250 μL of 5 μM (FITC
eq.) G4OH-(NH2-FITC) and G4OH-(NH2-FITC)-(PEG) solution as previously synthesized were
slowly injected in the channel containing the bacterial biofilms by piercing the 30G needle
through inlet silicon tube. Observation with a Zeiss 710 Confocal Laser Scanning Microscope
(Zeiss Microscope, Oberkrochen, Germany) commenced immediately after injection of the
dendrimers with the conjugated fluorophore. The penetration into the biofilm was assessed as a
function of time by taking 3D images every 15 min after injection of the conjugates, with the end
point being 45 min after the injection. The diffusion of G4OH-(NH 2-FITC) and G4OH-(NH2FITC)-(PEG) in PA biofilms grown under flow and synthetic mucus was determined using
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fluorescence recovery after photobleaching (FRAP). After adding 5 μM of FITC conjugates
(G4OH-(NH2-FITC) or G4OH-(NH2-FITC)-(PEG)) in the flow chamber, the inlet/outlet tubes
were clamped, and the system was equilibrated at room temperature for 1h before imaging.
FRAP experiments were also conducted using a Zeiss 710 Confocal Laser Scanning Microscope
at 40× magnification and 3.8 zoom with laser excited at 488 nm. The image resolution was 80
nm/pixel. A circular area with rardius (r) of 5 μm was rapidly bleached at 100% laser intensity.
Fluorescence recovery was monitored over 40 s time period (1s interval between two images)
with initial attenuated laser power. Fluorescence intensity profiles were obtained and processed
using the ZEN software. The time to recover 50% of fluorescence in biofilms and synthetic
mucus (τ), and mobile fraction of FITC labeled dendrimer conjugates were determined.
2.2.2.4 Antibiofilm Activity of Dendrimer-Tobra Conjugates in PA Biofilm Model
2.2.2.4.1 Crystal violet assay (Biomass measurement)
Overnight bacterial culture (PAO1 or FRD1) was diluted to OD 600 = 0.02 with LB broth.
A volume of 100 µL of bacteria suspension was inoculated in 96-well plates and grown for 24h
at 37˚C. After the biofilm was formed, planktonic bacteria were aspirated. Biofilm was carefully
rinsed with sterile PBS and 100 µL of each treatment was added. G4OH-(Tobra) and G4OH(Tobra)-(PEG) solutions were prepared contain equivalent concentrations to free Tobra, and
serially diluted with LB medium to the desired concentrations. The biofilms were incubated with
treatment at 37˚C for 24 and 48h. Crystal violet assay was performed to determine the biomass
of treated biofilms [86]. Treated biofilms were then rinsed with PBS, and 125 µL of freshly
prepared 0.1% crystal violet solution was added to each well and stained for 10 min at room
temperature. Subsequently, crystal violet solution was removed, followed by several washes with
DI water to avoid any residual dye that may non-specifically stain adherent bacteria. The stain
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was air dried and dissolved with 30% acetic acid. The absorbance of crystal violet staining was
measured at 530 nm using a multimode microplate reader (Synergy H1, Biotek, Winooski, VT,
USA). At least 4 replicates (n = 4) were performed for each condition. The inhibitory percentage
was calculated using equation 1, where control are wells with no treatment.
Inhibition% = 100% -

(

)
(

)

Eq. 1

× 100%

2.2.2.4.2 Bacteria viability assay
Biofilm formation and treatment process was similar to that described above. Briefly,
overnight fresh FRD1 (GFP tagged) culture was diluted to OD600 = 0.02 with LB broth. A total
of 100 µL bacteria suspension was cultured in 96-well plate for 24h until biofilms were formed.
The biofilm was treated with free Tobra, PEGylated dendrimer-tobra and non-PEGylated
dendrimer Tobra for 48h (as well as non-treatment control). After treatment, nonadherent
bacteria was carefully washed out. Propidium iodide (PI, 100 µL of 15 µM) was added and
stained for 15 min, followed by one rinse with PBS. Biofilm was visualized by Confocal Laser
Scanning Microscope (CLSM) Zeiss 710. Laser light at 488 nm and 516 nm was used for GFP
(green) and PI (red) excitation respectively. For each well, the maximum thickness of the biofilm
at the center of the well was measured in advance (from the bottom to the top of biofilms), and
three positions were chosen for z-stack acquisition. Focal plane was acquired at the middle of the
biofilm regarding the pre-measured thickness, the other two stacks were recorded at 1/3 height
from the bottom and 1/3 height from the top of biofilm. Red (dead) and green (live) fluorescence
densities from all three images were integrated for each well, and the Live% distribution was
defined as the relative fluorescent density proportion of green/(red+green). Three replicates (n=3)
for each sample were performed in this experiment [87].
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2.2.5 Statistical Analysis
All data are presented as a mean value ± standard error of the mean (SEM). The means
were calculated from a minimum of at least three independent measurements (n ≥ 3). Student’s ttest, two-way analysis of variance (ANOVA) followed by Tukey’s Multiple Comparison Test
was performed using GraphPad Prism 7 software (version 7.1.0). Means were considered
statistically significant if p < 0.05.

2.3. Results and Discussion
2.3.1 Synthesis and Characterization of FITC-labeled Dendrimer Conjugates and
Dendrimer-Tobra Conjugates
Different applications of PEG in biomedical relevant areas have been extensively studied.
Coating the surface of nanoparticles with PEG is a common strategy for improving drug and
gene delivery [88]. PEGylation can also be employed to alter the physiochemical properties of
dendrimers, including size [81] and surface charge [70], and improving solubility of dendrimer
conjugated with hydrophobic payloads [72]. Dense PEGylation can shield the surface charge and
further reduce the interaction with surface lining fluid and tissue extracellular matrix, leading to
enhanced “biological barrier” penetration [91][88]. We thus hypothesized that PEGylation of
dendrimer conjugates that carry a positive charge would lead to enhanced diffusion/distribution
in mucus and in bacterial biofilm ECM.
In order to test this hypothesis we prepared two groups of G4OH dendrimer conjugates:
one carrying protonatable amines (-NH2) and FITC-conjugated for tracking the dendrimers in
relevant biological matrices using various microscopy techniques, and the other group with
Tobra conjugated, to test their potential in treating biofilms. Their PEGylated analogs were
prepared to shield the protonated amines (from -NH2 groups modifying the surface and/or from
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Tobra) leading to the formation of slightly negatively charged/neutral dendrimers to contrast
with the positively charged (no PEG) conjugates. The amine groups of Tobra can be protonated
under physiological conditions or biofilm relevant conditions (slightly acidic) due to its pKa [93].
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We started by derivatization mPEG (1KDa) to carboxylic acid terminated mPEG-COOH,
by reacting mPEG with succinic anhydride. mPEG-COOH was further modified to mPEG
anhydride using DCC as dehydration reagent. The resulting products were characterized by
MALDI, 1H-NMR and

13

C-NMR. Subsequently (6-Boc-amino) hexanoic acid (linker) was

coupled to G4OH via Steglich esterification (G4OH-NHBoc), followed by removal of Boc
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groups as show in Scheme 1A (G4OH-NH2). To obtain the PEGylated analogs, mPEG
anhydride was reacted with G4OH-(NHBoc) via esterification in the presence of pyridine,
followed by Boc groups deprotection to form G4OH-(NH 2)-(PEG) (Scheme 1B). Finally, FITC

41

was coupled with G4OH-NH2 to prepare G4OH-(NH2-FITC), and with G4OH-(NH2)-(PEG) to
prepare G4OH-(NH2-FITC)-(PEG) respectively.
Scheme 1: Schematic diagram of key steps of the synthetic routes utilized for the preparation of

(A) G4OH-(NH2-FITC) (4); (B) G4OH-(NH2-FITC)-(PEG) (7); (C) Boc-protected tobramycin
succinate (TB-SA); (D) G4OH-(Tobra) (9); and (E) G4OH-(Tobra)-(PEG) (11). Reagents and
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conditions: (i) EDC/DMAP, DMF, RT, overnight; (ii) 4M HCl in dioxane, 30 min; (iii) TEA,
DMF, RT, overnight; (iv) DMAP, pyridine, DCM, RT, overnight; (v) 60˚C, 5h, DMF/H 2O; (vi)
DIPEA, DMF, overnight; (vii) EDC/NHS, DMF, RT, overnight.

Figure 1: MALDI-TOF spectra of (A) G4OH (blue), G4OH-(NH2-FITC) (4) (red), and G4OH-(NH2-FITC)(PEG) (7) (black), and (B) G4OH (blue), G4OH-(Tobra) (red) (9) and G4OH-(Tobra)-(PEG) (black) (11).

The characteristic multiplets of 1H-NMR spectrum appeared at 6.5~7.5 ppm and 8.1 ppm,
indicating FITC conjugation and each dendrimer was labeled with two to three FITC molecules
(Figure 2A & 2B). The appearance of peaks (d and g) at 2.2 ppm (-CO-CH2-CH2-) and 2.7 ppm
(-CH2-CH2-NH2) respectively in the 1H-NHR spectrum confirmed the existence of the linker
(Figure 2A). Each of 10 molecules of linker was conjugated by integrating protons of peak d and
g, which was consistent with the peak shift of molecular weight (MW) from 5370 Da to 7489 Da
in MALDI-ToF (Figure 1A). 1H-NMR peaks (peak 1) corresponding to PEG appeared at 3.1
ppm (Figure 2B). Peak integration yielded an average of 19 PEG1KDa attached per dendrimer,
in agreement with MW shift to 30075 Da observed in the MALDI-TOF spectra (Figure 1A).
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G4OH-(NH2-FITC) and G4OH-(NH2-FITC)-(PEG) were used in penetration/distribution and

1

Figure 2: H NMR spectra of G4OH-(NH2-FITC) (red) (4) and G4OH-(NH2-FITC)-(PEG) (black) (7).

diffusion tests in CF relevant matrices (see Section 3.3).

The synthetic strategy for the preparation of dendrimer-Tobra conjugates was designed
based on several considerations, as shown in Scheme 1: (1) the introduction of amine groups (NH2) to the surface of G4OH; (2) structure modification for Tobra and conjugation to dendrimer
via a hydrolysable bond, (3) PEGylation of dendrimer-Tobra conjugates to achieve hypothesized
physical characteristics. We chose polyester dendrimers as compared with other types of
dendrimers (eg. PAMAM dendrimer) due to their biodegradability under physiological
conditions, and possessing enough surface groups to maintain drug loading capacity (48 surface
hydroxyl groups) [81]. However, one of the challenges of constructing dendrimer drug
conjugates is to select appropriate chemical transformations with high efficiency for both
reaction partners. Aminoglycoside antibiotics bind to the ribosomal RNA (rRNA) decoding Asite and cause translation infidelity. It has been reported that all amine groups of tobramycin can
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bind to rRNA via electrostatic interactions, while only two out of five -OH can form hydrogen
bonds to rRNA [94], indicating that amine groups can be essential for the antimicrobial activity
and we thus did not use those groups for derivatization. We selected to modify primary -OH at
C6 position, which has neither direct nor water mediated contact with rRNA [94][95]. All amine
sites were initially protected by Boc group to prevent any undesired side reactions during the
chemical modification process (Scheme 1C). (Supplemental information: 1H -NMR results show
a peak at 1.39 ppm ((-CH3 of Boc), indicating a successful protection of amine group. The
appearance of Tobra-Boc (TB; [TB+Na]+ = 990.121, [TB+K]+ = 1006.075) in MALDI indicated
tobramycin is fully protected with Boc.) Subsequently, the –OH group was activated with
succinic anhydride to provide a carboxyl group and succinic acid was connected to Tobra
through an ester bond (Scheme 1C). (Supplemental information: In the 1HNMR spectrum, the
peak at 2.51-2.59 ppm (-CH2- in succinate) and shift of -CH2- (2Hb) from 3.92-3.40 to 4.29-4.18
ppm revealed successful succination of Tobra.)

(After obtaining Boc-protected tobramycin

succinate (TB-SA), we tried to directly react -COOH with the terminal -OH of dendrimer.
However, it was unsuccessful. The reaction is inefficient, and dimers/trimers of TB-SA were
observed. Data not shown here.) Due to the low reactivity of hydroxyl groups of G4OH, we
modified the surface of the dendrimer with amine groups as described earlier (Scheme 1A). The
conjugation of the linker not only improved the reactivity of G4OH, but also provided spacing
(six carbon chain) from dendrimer surface which may mitigate the steric hindrance as the drug is
conjugated and released (either pH-responsiveness or enzymolysis) [276]. This time the reaction
provided 17 amine groups per dendrimer based on MALDI-ToF results (See Supplemental
information: The peak shift in MW shown in the MALDI-ToF spectrum from 5370 Da to 7308
Da further confirmed the product). Finally, the conjugation of amine modified dendrimer
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(G4OH-NH2) with Boc-protected Tobra succinate (TB-SA) was performed using EDC/NHS
chemistry, and then Boc protecting groups were removed to expose amine groups on tobramycin
(Scheme 1D). The 1H-NMR and mass spectra of resulting dendrimer-Tobra conjugates are
summarized in Figure 3D. The peak A1 (5.4 ppm), C1 (5.1 ppm) and A3+B2 (2.1 ppm) are
related to Tobra. The appearance of peak 3 (2.5 ppm) revealed succinate (-CH2-) coupled with

1

Figure 3: H NMR spectra of Tobra (purple), G4OH-(Tobra) (red) (9), G4OH-(Tobra)-(PEG) (black) (11).

Tobra. The molecular weight shift from 7308 Da to 12714 Da in the mass spectrum indicated
that an average of 9 Tobra were conjugated on each dendrimer (Figure 3D).

To avoid the inactivation of amine groups on Tobra, PEGylation of G4OH-Tobra was
carried out right after conjugating TB-SA to G4OH-NH2, using mPEG anhydride (Scheme 1E).
Deprotecting Boc groups was subsequently performed (Scheme 1E). This reaction resulted in a
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high degree of PEGylation with DMAP as catalyst as determined by 1H-NMR. The characteristic
peak (-CH3) from mPEG can be seen at 3.1 ppm, which was also used to determine the number
of mPEG chains by proton integration (Figure 3E), which was calculated to be 17 PEG, in
agreement to the results observed from the MALDI-ToF analysis (Figure 1B). However, the
number of conjugated Tobra decreased to 7. It is possible that a residual amount of HCl in
deprotection process was introduced in the dialysis step with aqueous solvent, which caused
certain degree of hydrolysis of ester bond.
A summary of the intermediates and final dendrimer products, along with their chemical
and physical characterization, including the number of conjugated linker with terminal -NH 2,
tobramycin, PEG, hydrodynamic size and surface charge, is listed in

Table 1.

Table 1: Characteristics of the generation four (G4), polyester dendrimer (G4OH) conjugates.
Number of NH2, PEG, FITC and tobramycin (Tobra) conjugates were determined by 1H-NMR.
Size (hydrodynamic diameter, HD), and zeta potential (z) were determined by light scattering
(LS). Numbers in parentheses refer to intermediates/products as shown in Scheme 1.

Dendrimer Conjugates

nNH2

nPEG

nFITC

HD ± s.d. (nm)

z ± s.d. (mV)

G4OH (1)

0

0

0

1.2 ± 0.4

0.1 ± 0.2

G4OH-(NHBoc) (2)

10

0

0

N/D

N/D

G4OH-(NHBoc)-(PEG) (5)

10

19

0

N/D

N/D

G4OH-(NH2-FITC) (4)

10

0

2.5

1.0 ± 0.1

+33.9 ± 2.2

G4OH-(NH2-FITC)-(PEG) (7)

10

19

2.2

6.3 ± 0.4

-4.7 ± 0.3
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Dendrimer Conjugates

nNH2

nPEG

nTobra

HD ± s.d. (nm)

 ± s.d. (mV)

G4OH-NH2 (3)

17

0

0

3.6 ± 0.3

+40.1 ± 2.5

G4OH-(Tobra) (9)

*53

0

9

5.1 ± 0.2

+32.0 ± 0.9

G4OH-(Tobra)-(PEG) (11)

*35

17

7

6.8 ± 0.1

+4.1 ± 5.5

N/D = not determined as these dendrimer conjugates are not soluble in aqueous solution due to the high number of Boc groups; * The
number of total NH2 shown as a sum of all terminal -NH2, including -NH2 from both linker and Tobra (5 per molecule).

Light scattering results showed that upon converting surface functional groups from -OH to NH2, an increase of surface charge was observed, from neutral (G4OH) to positively charged
(+33.9 mV for compound 4 and +40 mV for compound 3). It is expected that the amine group
can be protonated (-NH3+) in aqueous solution, and thus the positive charge. Similar
phenomenon was observed on G4OH-Tobra with a positive charged conjugate (+32 mV for
compound 9). Although each Tobra can provide five amine groups, the overall surface charge is
comparable to that of G4OH-NH2, indicating that the basicity of primary amine groups from
Tobra is weaker than that from linker [93]. PEGylation of the conjugates led to a decrease in the
surface charge of G4OH-(NH2-FITC)-(PEG) and G4OH-(Tobra)-(PEG) to slightly negatively
charged/neutral (Table 1). These results are in accordance with previously reported literature
[96][91]; ether groups in PEG are capable of screening surface charges of protonated amines via
strong electrostatic interactions.
The tethering of linker caused an increase of hydrodynamic diameter (HD) of G4OH
from 1.2nm to 3.6 nm for G4OH-NH2, and a further increase in HD was seen upon the
conjugation of Tobra, to 5.1nm (G4OH-(Tobra)). Coupling G4OH-NH 2 with FITC, on the other
hand, resulted in a size decrease to a HD of around 1 nm, which was in the same scale of bare
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G4OH. This could be attributed to the carboxylic acid group present in FITC, which can form
hydrogen bonding with the linker’s amine group. The original repulsion force between solvated
surface -NH3+ groups in G4OH is reduced upon conjugation, leading to a possible collapse of the
dendrimer structure and reduction in HD [97]. PEGylation also significantly impacted the size of
nanocarrier: increases in HD from 1.0 nm (G4OH-(NH2 -FITC)) and 5.1 nm (G4OH-(Tobra)) to
6.3 nm (G4OH-(NH2 -FITC)-(PEG)) and 6.8 nm (G4OH-(Tobra)-(PEG)) were observed,
respectively.
We have thus obtained highly positively charged dendrimers conjugated with either FITC or -Tobra and were able to reduce the charge of those conjugates to neutral/slightly
negatively charged upon PEGylation, paving the way to test our hypothesis. We will further
discuss how the PEG layer surrounding the dendrimer core impacted the behavior of those
carriers in matrices relevant during bacterial biofilm infections.
2.3.2 Penetration and Diffusion of FITC Labeled Dendrimer Conjugates in Synthetic
Mucus and PA Biofilm
To assess the impact of the surface properties of the dendrimer conjugates on their
behavior in CF relevant matrices, confocal microscopy was used to visualize the penetration of
G4OH-(NH2-FITC) and G4OH-(NH2-FITC)-(PEG) through PA biofilms. The PA biofilm was
established in a flow chamber system described earlier (Figure 4). Both PAO1(non-mucoid) and
FRD1 (mucoid) strain were investigated, with the PAO1 being the mostly used strain in in vitro
studies, and the FRD1 being more clinically relevant as [98].
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Figure 4: Schematic of the flow system used to prepare the bacterial biofilms. (A) Syringe pump with
media reservoir; (B) bubble trap; (C) flow chamber; and (D) waste container.

The 3D images were reconstructed from confocal microscope images obtained at varying
time points 30 min after contacting the biofilm with either positively charged or PEGylated
dendrimers as discussed earlier (Figure 5). The neutral dendrimer conjugates (G4OH-(NH2FITC)-(PEG)) exhibited a faster penetration and an improved distribution in both FRD1 and
PAO1 biofilms when compared to the positively charged dendrimer conjugates (G4OH-(NH 2FITC)). Distribution of neutral dendrimer conjugates was nearly complete within the biofilms
after 15 min contact, while positively charged dendrimers seems to form aggregates and not
completely nor homogeneously distribute with the biofilms, only appearing at exterior layers.
The distribution was especially hampered for the positively charged dendrimers in the FRD1.
These results seem to suggest that the neutral surface charge of PEGylated dendrimer conjugates
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promote their penetration deeper into the biofilm layers and at a greater extent and uniformity

Figure 5: Representative confocal microscopy images indicating penetration and distribution ability of of
FITC-labeled neutral (G4OH-(NH2-FITC)-(PEG) ) and positively charged ( G4OH-(NH2-FITC) )
dendrimer conjugates through FRD1 (A&B) and PAO1 (C&D) biofilms. Images taken at 5, 15, and 30
min after biofilm exposure to dendrimer conjugates.

then their positive counterparts.

The diffusion of dendrimer conjugates in relevant biofilm matrices was quantitively
measured using FRAP. These represent complementary results to those discussed above.
Diffusion is inversely related to t1/2 [99][100]. As biofilms are usually embedded in thick and
sticky pulmonary mucus, such viscous mucus also represents an additional physical barrier for
antibots to effectively reach relevant doses in the biofilm of CF patients’ lung. Diffusion in
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mucus was thus determined first. FRAP results show that neutral dendrimer conjugates
consistently have shorter t1/2 than positively charged molecules (Figure 6A), indicating that
neutral dendrimer conjugates diffused faster in the synthetic mucus than positive dendrimer
conjugates. The impact of surface charged is greater in PAO1 biofilms (Figure 6C), and most
pronounced in the mucoid FRD1 PA biofilms (Figure 6B), when t1/2 is 1/3 fold smaller (faster
diffusion) for the PEGylated dendrimer compared to the positively charged conjugates.

Figure 6: Diffusion (upper panel) and mobile fraction (lower panel) of FITC-labeled, neutral (G4OH(NH2-FITC)-(PEG) ) and positively charged ( G4OH-(NH2-FITC) ) dendrimer conjugates in (A)
synthetic mucus, and also in (B) FRD1 and (C) PAO1 biofilms. Dendrimer conjugates were added to
synthetic mucus. Bacterial biofilms were grown in the flow chamber and allowed to equilibrate for 1 h
after addition of the dendrimer-FITC conjugates. Diffusion coefficient and mobile fraction were
measured using fluorescence recovery after photobleaching (FRAP). The data represent the mean value ±
SEM of n = 5 independent experiments. A student’s t-test was used to compare the data; *p<0.05,
**p<0.01, and ***p<0.001.

Interestingly, however, while the mobile fraction of neutral dendrimer conjugates is
higher than that of positive dendrimer conjugates in FRD1 (Figure 6D) and PAO1 biofilms
(Figure 6E), no difference in mobile fraction was observed in the synthetic mucus (Figure 6C),
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perhaps due to the simplistic synthetic mucus used in this work compared to CF patient sputum
[101][102]. A relatively low mobile fraction suggests a significant binding of positively charged
dendrimer to elements of the bacterial biofilm. The broadening of mobile fraction for positively
charged particles in biofilms is likely caused by the highly heterogenous structure of biofilm
itself, including dense bacteria clusters and water channels with low bacteria density. It has been
reported that the water channel in bacteria biofilm could be between 10 to 30 µm, which can be
found both at the outer edge as well as deeply penetrated in the structure [103]. Taken together, it
can be concluded that positively charged dendrimer conjugates strongly interact with (synthetic
mucus) and biofilm components, in contrast with their neutral analogs.
This improved diffusivity and mobile fraction of the neutral conjugates in the biofilms
can be explained by the bacterial biofilm architecture. Bacterial biofilms are formed as a
community of multicellular microorganisms that adhere to a living or inert surface, which is
surrounded by self-secreted extracellular matrix called EPS [31][104]. It is known that EPS plays
an important role in developing biofilm-specific resistance against antimicrobial reagents
[105][31][26]. Composed of polysaccharides, proteins, eDNA, and water, EPS provides a stable
microenvironment for bacterial proliferation [31][20]. As the pH value inside PA biofilm varies
from 5.5 to 7.0 [106], aminoglycosides, such as Tobra, which have multiple primary amine
groups, are easily protonated when entering the biofilm. Anionic polysaccharides (alginate, Psl
& Pel) secreted by bacteria [107][108] and other biopolymers, such as eDNA, in the EPS can
bind to aminoglycosides via electrostatic interaction and further retard their penetration . The
slow penetration through EPS also provides greater opportunity for enzymes to inactivate
antibiotics, further attenuating overall active drug concentration, which may lead to an adaptive
resistance within the biofilm [21]. Moreover, in CF patients, biofilms are embedded in thick and
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sticky pulmonary mucus. Unlike regular mucus, in which mucin is the main constituent, CF
sputum usually has an altered composition with an increasing amount of DNA, filamentous actin
and lipids, which all contribute to the higher viscosity comparing to healthy people [109][18].
Such viscous mucus represents as an additional physical barrier that prevent the drug from
reaching the bacteria. To disrupt these barriers, Dnase and alginase have been demonstrated to
synergistically improve the antibiofilm efficiency of antibiotics (eg. Tobra) [110]. Thus, the
therapeutic efficacy is significantly impacted by the failure of aminoglycosides to penetrate
through the biofilm and the mucus layer.
In this context, the use of nanocarrier can be explored to overcome the resistance.
Liposomes and polymer-based formulations encapsulated with antibiotics have been widely used
in the study of CF mucus and bacteria biofilm. For example, it has been reported that liposome
encapsulated amikacin can readily penetrate into the biofilm and exert a sustained release profile
[113]. Whereas, due to the dense structure of these CF related barriers, the bioavailability of
these nanoparticles can be limited by the obstruction of the polymer network. The reported
mucus mesh pore size ranges from 100 to 500 nm [114][69]. Correspondingly, polystyrene
nanoparticles at 500 nm were observed to be greatly excluded from CF sputum and the mass
percentage transport was only 1/40 compared with that of 120 nm particles with the similar
surface properties [114]. Although a majority of extensively applied nanoparticles which falls in
100~200 nm range can partially penetrate through CF mucus layer, the mobility of these
nanoparticles can be significantly reduced 10-1000 fold by CF related matrix compared with
water [48][115][116]. These results suggest that the other important factor involved in diffusion
through barrier can be the surface charge, as charged particles are likely to interact with matrix
components via electrostatic interaction.
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Meanwhile, PEGylation is known to significantly reduce such interactions of
nanoparticles and biomacromolecules in mucus and ECM [91][88][92]. It was also noted that for
polymeric nanoparticles (eg. PLGA particles), the surface coverage percentage of PEG needs to
be sufficiently high with a low MW of PEG (2-5kDa) to achieve a “brush” configuration.
Although larger PEG molecule like 10kDa can also shield surface charge and obtain neutral
molecule, no improvement of diffusion was observed, possibly because of decreased the meansquare-displacement of PEG [117]. Since dendrimer conjugates synthesized in this paper are
under 10 nm, the obstruction effect was expected to be minimized under such circumstances. The
strong binding of positively charged dendrimer conjugates in bacteria biofilm can be attributed to
multivalent amine groups on the surface of dendrimer, and possibly aggregation of
macromolecules and dendrimer themselves. Comparing with PAO1, FRD1 not only secrete
polysaccharides like Psl and Pel, but also produce large amount of alginate as a mucoid strain, to
maintain architecture when forming biofilm. It should be noted that the mobile fraction in FRD1
biofilm tends to be even lower than that in PAO1. This could be potentially explained by a
reduction in electrostatic interaction between the dendrimer and the less complex/charged matrix
components of PAO1. A similar trend as seen in mobile fraction was seen with diffusivity when
we compared FRD1 and PAO. On the other hand, diffusivity and mobile fraction (close to 100%)
of PEGylated dendrimer conjugates in all three groups were comparable with each other,
regardless of the difference between matrices, achieving significant mobility improvement.
When put together, the results discussed in this aim support our hypothesis that neutral
dendrimer conjugates promote penetration, distribution and diffusion of the conjugates through
CF relevant matrices. As the synthesized dendrimer Tobra conjugates discussed next have
similar physiochemical properties to the model molecules here, we expect the that PEGylated
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dendrimers would be likely to diffuse faster through the much in the CF lung and also more
evenly distribute through the biofilm, thus overcoming some critical limitations of existing
antibiotic formulations in eradicating PA biofilm.
2.3.3 Antimicrobial Activity of Dendrimer-Tobra Conjugates against Planktonic PA
Before assessing the effect of the dendrimer-Tobra conjugates on PA biofilms, we
performed minimum inhibitory concentration (MIC) experiments in planktonic PA (both PAO1
and FRD1) with both fully released Tobra (accelerated hydrolysis) and intact conjugates to
assess (i) whether the synthetic steps used for Tobra conjugation had any impact on the
biological activity of released Tobra and (ii) whether conjugates before full release may detain
similar bioactivity as released Tobra. The MIC of dendrimer-Tobra conjugates, free Tobra,
unmodified dendrimer and the corresponding hydrolysis products at the same equivalent
concentration as free Tobra are summarized in Table 2.
Table 2. Minimum Inhibitory Concentration (MIC) (µg/mL) against planktonic P. aeruginosa
PAO1 and FRD1 strains.
Before Accelerated Hydrolysisa
µg/ml

After Accelerated Hydrolysisb

Free Tobra

G4OH(Tobra)

G4OH(Tobra)-(PEG)

G4OH

Free Tobra

G4OH(Tobra)

G4OH(Tobra)-(PEG)

PAO1

1

16

32

> 64

1

2

2

FRD1

1

16

64

> 64

1

2

2

For all MIC measurements, n = 3 independent replicates. aCompounds were dissolved in buffer (pH=7.4); as
received (Tobra, G4OH) or synthesized conjugates. bAccelerated hydrolysis conditions: pH of solutions were
adjusted to pH=10, and stirred overnight. Subsequently, pH was adjusted back to 7.4, and all the hydrolyzed
products were used to perform the MIC assay.
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The MIC determined for free Tobra of 1 µg/mL is within the range reported in the
literature for various strains, including those isolated from CF patients, reproted between 0.5 to 4
µg/mL [110][118]. G4OH-(Tobra) without being subjected to accelerated hydrolysis (i.e. very
small amounts of Tobra are released within the time of the experiment due to conditions) showed
a MIC of 16 µg/mL against both PAO1 and FRD1. The MIC of G4OH-(Tobra)-(PEG) displayed
higher MIC at 32 µg/mL against PAO1 and 64 µg/mL against FRD1. The MIC value determined
for unmodified G4OH was of > 64 µg/mL, indicating no activity by itself. Combined, these
results support a view that Tobra needs to be released for biological activity. As expected, we do
not believe Tobra will be transported across intact walls of bioavailable PA cells, and reductions
in MIC are mostly from the expected (small amounts of) released Tobra that is internalized in
[121][122]. The permeation process of aminoglicosides has been demonstrated to be initialized
by electrostatic binding to the bacterial outer membrane, followed by removing or replacing
Mg2+ at the binding site of lipopolysaccharides (LPS) [122][123]. Some activity may also come
from the physical interaction of the dendrimer conjugates with cell walls as observed for highly
positively charged amine-terminated PAMAM [124]. This may explain why G4OH-(Tobra) has
a lower MIC compared to the PEGylated analog.
The MIC results of the conjugates subjected to accelerated hydrolysis indicate that the
Tobra bioactivity is highly maintained after all the synthetic steps and its release from the
dendrimer. The products of hydrolysis, which includes released Tobra and smaller fragments of
the polyester dendrimer and PEG (which have no activity in these systems – results not shown
here), yield a MIC of 2 µg/mL against both strains, which is again within the range reported for
free Tobra, and only slightly greater than our free Tobra MIC value.
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2.3.4 Antibiofilm Activity of Dendrimer-Tobra Conjugates in PA Biofilm Model
Now that we have demonstrated that the bioactivity of Tobra is highly maintained during
the various synthetic steps leading to the preparation of the conjugates and upon release, we turn
our attention to determining the potential of the conjugates with regards to their antibiofilm
activity. In order to do so, we assessed both biomass reduction and bacteria viability in a static
biofilm model.
Biomass assay was performed by a colorimetric method using crystal violet staining,
which binds not only to the biofilm matrix but also all embedded adherent cells. The results are
summarized in Figure 7.

Free Tobra and Tobra from the neutral G4OH-(Tobra)-(PEG)

conjugates led to a dose-dependent response in inhibiting the growth of FRD1 biofilm (Figure
7A and B), especially after 24h (Figure 7A) of treatment. The inhibitory activity of Tobra in the
cationic G4OH-(Tobra) conjugate was very low at 24h and no dose response was observed. For
all concentrations, no significant difference was observed between G4OH-Tobra-PEG and free
Tobra at 24h (Figure 7A). However, upon increasing the treatment time to 48h, the inhibitory
percentage of G4OH-Tobra-PEG exceeded that of free Tobra, where 4 µg/mL, 8 µg/mL and 16
µg/mL showed 64% vs 36%, 77% vs 49% and 72% vs 53% growth inhibition respectively
(Figure 7B).
The results indicate a significant stronger antibiofilm activity of the neutral G4OHTobra-PEG conjugate than either free Tobra or the cationic conjugate, especially at higher Tobra
eq. concentrations and longer contact times.

It is important to note that these benefits of

conjugation of Tobra to neutral dendrimers are being observed in spite of the fact that 48h
contact time is not expected to promote full release of Tobra from the conjugates, and thus while
total Tobra loaded is the same in all systems, released Tobra is expected to be always at lower
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concentrations than free Tobra. It is also important to note that we expect further benefits of the
neutral conjugates in vivo as the biofilm will be embedded in the mucus layer, and those
conjugates have shown high diffusion and mobile fraction in mucus.
Interestingly, the same phenomenon was not observed in the non-mucoid PAO1 biofilm
(Figure 7C and D). Although free Tobra maintained the same inhibition pattern as in FRD1,
PEGylation did not significantly improve the biofilm inhibitory activity at either time points,
being equivalent to free Tobra at 48h contact (Figure 7D). It is worth to highlight again the fact
that we do not expect conjugated Tobra to be fully release at 48h, and thus the gains are expected
to be enhanced with time of exposure for the conjugate. At 24h treatment, free Tobra inhibited
PAO1 biofilm to a greater degree (from 1.6 to 2.7 fold) comparing to both dendrimer drug
conjugates at 8 µg/mL and 16 µg/mL (Figure 7C). Upon extending treatment time to 48h, the
inhibitory activity of free drug and dendrimer drug conjugates were not significantly different
(Figure 7D).
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Figure 7: P.aeruginosa biofilm growth inhibition with the treatment of G4OH-(Tobra), G4OH-(Tobra)-(PEG)
and free Tobra (positive control) as a function of Tobra equivalent concentration (µg/mL) – flow-based
biofilm. The treatments were added to 24h-old biofilm and total biomass (bacteria and extracellular matrix)
was measured. Upper panel shows inhibitory activity of treatment on FRD1 after 24h (A) and 48h (B) exposure
to treatment; lower panel for PAO1 after 24h (C) and 48h (D) exposure to treatment. The data represent the
mean value ± SEM of n = 4 independent measurements. The data was analyzed by Two-way ANOVA with
multiple comparison test.

This difference in behavior for PAO1 and FRD1 may be explained by the differences in
ECM components for those two strains. As a mucoid strain, FRD1 produces copious amount of
alginate whereas PAO1 does not [125]. Alginate is thought to be the primary aminoglycoside
binding components in biofilm because of its negative charge [126]. Free Tobra may penetrate
faster through PAO1 biofilm than FRD1. This could result in an artificially enhanced antibiofilm
activity of free Tobra against the less biologically relevant PAO1 biofilm. Although PEGylated
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dendrimer-Tobra did not inhibit the growth of PAO1 biofilm as efficiently as FRD1, FRD1 could
probably be a more clinical-related representative of PA biofilms, as literature indicates that a
significant number of PA isolates from CF patients are of mucoid strain, and the production of
alginate may influence the CF lung environment [98][126].
To further evaluate the potential of the conjugates and the impact of the surface charge on
their ability to induce the cell death of bacteria in the biofilm, we determined cell viability
(live/dead) in a static biofilm model of FRD1 cells (clinically relevant strain) expressing GFP
(green fluorescence) and PI stain (red fluorescence). As PI can only permeate through the
membrane of dead bacteria to stain intracellular DNA, we define green and red fluorescence as
live and dead bacteria respectively – a caveat being that PI may stay extracellular DNA.
The activity of free Tobra and dendrimer-tobra conjugates against mature FRD1 biofilm
exposed to treatment for 48h was assessed by confocal microscopy. Bacterial viability was
quantified as live bacteria percentage in biofilm (fraction of live/total). A comparison of bacteria
viability among negative control and all treatment groups is shown in Figure 8. The treatment
groups included negative control (LB media), free Tobra, G4OH-(Tobra) and G4OH-(Tobra)(PEG). We chose 1 µg/mL, 8 µg/mL and 16 µg/mL as representative concentrations. 1 µg/mL is
the MIC of free Tobra, while 8 and 16 µg/mL of Tobra eq. in dendrimer conjugates have been
demonstrated to show efficient antibiofilm activity in the crystal violet assay.
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Figure 8: P.aeruginosa (FRD1) biofilm growth inhibition with treatment of free Tobra and G4OH-Tobra
conjugates under static growth conditions – 48h treatment exposure. (A) Live % of negative control (no treatment
group) and free Tobra as a function of Tobra (1µg/mL, 8 µg/mL and 16 µg/mL). (B) Live % of G4OH-(Tobra)
and G4OH-(Tobra)-(PEG) treatment as a function of Tobra eq. concentration. Results were normalized by the
value of Live% of negative control. The data represent the mean value ± SEM of n = 3 independent experiments.
The statistical significance was analyzed by student’s t-test. *p<0.05 and **p<0.01. Additional comparisons
(table) provided in Supplemental Information.

As shown in Figure 8A, the Live% of negative control group is 47.4 ± 3.9%, indicating
some bacteria in the biofilm have already died without treatment. This fraction is comparable
with previously published data [87]. Although a trend of reduced live cells percentage has been
seen with increasing Tobra concentration, 1 µg/mL (37.25 ± 4.8%) and 8 µg/mL (33.1 ± 13.5%)
of treatment failed to show a statistically significant difference compared to negative control. As
expected, a minimum concentration that can inhibit visible bacteria growth in planktonic form
cannot show a similar activity against bacteria in biofilm to the same degree, not even with 8
times of MIC (8 µg/mL). Only 16 µg/mL reduced Live% to 10.5 ± 2.6%, indicating that a much
higher concentration of free Tobra than MIC in planktonic state was required to kill bacteria in
biofilm while still not achieving 100% eradication.

62

The efficacy of PEGylated dendrimer-Tobra (neutral) and the non-PEGlyated analog
(positively charged) against FRD1 bacteria grown in static biofilm assays were also compared
(Figure 8B). The bacteria viability in mature FRD1 biofilms after 48h treatment of G4OH(Tobra) and G4OH-(Tobra)-(PEG) were normalized by negative control. No significant
difference was observed between the live bacteria in biofilm treated with PEGylated and nonPEGylated dendrimer-tobra conjugates at 1 µg/mL. However, G4OH-(Tobra)-(PEG) showed a
significant higher activity than G4OH-(Tobra) at both 8 and 16 µg/mL, leaving less live bacteria
in the biofilm. Interestingly, it appeared that increasing the treatment concentration did not result
in further bacterial killing ability of G4OH-(Tobra), but quite the opposite, the % Live cells
increased compared to control [127]. It also has been reported that Tobra may bind to alginate,
which is an important component in the biofilm matrix secreted by PA mucoid strains [33]. A
visible aggregation by adding free Tobra to alginate has been seen, further demonstrating their
ionic interaction [129]. For non-PEGylated dendrimer conjugates, as there is an average of 9
Tobra connected per dendrimer and the surface charge is highly positive (+32.0 ± 0.9 mV), we
could expect an even stronger interaction between G4OH-(Tobra) and alginate than free.
Enriched amine groups on dendrimer can facilitate the aggregation, thereby sticking dendrimer
conjugates in matrix rather than permeating through it. The formation of dendrimer conjugatesalginate complex may further prevent the diffusion of other free dendrimer conjugates into
biofilm deep layers, likely resulting in a diminished antimicrobial efficacy in biofilm shown in
Figure 8B.
As shown in Figure 9, at 1 µg/mL all treatments were able to kill a very small fraction of
bacteria but failed to disrupt biofilm structure. Free Tobra exhibited significantly less live
bacteria but still a certain degree of observable colonized structure was preserved. Positively
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charged G4OH-(Tobra) displayed even more condensed hierarchical structure than free drug
(panel 2&5 of Figure 9). In contrast, biofilm treated with G4OH-(Tobra)-(PEG) at 16 µg/mL
showed a thinner and scanty architecture (panel 6 of Figure 9). Instead of biofilm microcolonies,
more single dead cells were distributed evenly in the microscopic field. Moreover, as
extracellular DNA (eDNA) is one of the key components in biofilm matrix, it is highly possible
that the red fluorescence not only represented dead cells in biofilm, but also reflect a certain
fraction of biofilm matrix. As we have discussed in biomass staining assay, free Tobra did not
eradicate biomass as efficiently as PEGylated dendrimer-Tobra. This could be a possible
explanation for the smaller value of bacterial viability of free Tobra than G4OH-(Tobra)-(PEG)
treatment. A higher level of biofilm matrix was seen in free Tobra group and under such
circumstances the dead cells were overestimated as a combination of dead cells + matrix.
Meanwhile, the amount of living bacteria was also clearly diminished, which is comparable to
free Tobra. These qualitative results are consistent with biomass reduction measurement in
crystal violet assay, further confirming enhanced penetration of neutral charged dendrimer drug
conjugate through biofilm, and strongly indicating the potential of of PEGylated dendrimer-tobra
over free Tobra in reducing PA biofilm loads.
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Figure 9: Representative CLSM images of P.aeruginosa FRD1 biofilms grown under static conditions in
96 well plates. The biofilms were treated LB broth (negative control), G4OH-(Tobra) and G4OH(Tobra)-(PEG) and free Tobra at low (1 µg/mL) and high (16 µg/mL) Tobra eq. concentration for 48h.
Viable (green) and dead (red) cells were visualized from eGFP expression in P.aeruginosa and
propidium iodide (PI) stain, respectively.
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2.4. Conclusion
In this work we demonstrated that PEGylation can shield positive charges on the surface
of G4OH dendrimer conjugates that arise due to the presence of protonable amine surface groups
and that such charge screening promotes the penetration and diffusion of dendrimer conjugates
in bacterial biofilm and synthetic mucus. Based on this observation, we developed new
nanoantibioic formulations with dendrimers as nanocarriers. We conjugated Tobra to G4OH
through a hydrolysable bond, producing conjugates that are cationic under physiological pH G4OH-(Tobra). Neutral analogs were prepared by further conjugating PEG to the dendrimer
surface yielding G4OH-(Tobra)-(PEG) conjugates. MIC studies against PAO1 and a more
clinically relevant mucoid strain (FRD1) indicate that the biological activity of Tobra is largely
preserved during the various conjugations and release steps. We also observed that neutral
G4OH-(Tobra)-(PEG) conjugates are able to suppress the growth of FRD1 PA biofilms to a
greater extent than free Tobra and the cationic conjugate G4OH-(Tobra) when the biofilms are
exposed to 8 and 16 µg/mL equivalent concentration of Tobra after 48h treatment exposure. The
strong ability of G4OH-(Tobra)-(PEG) to disrupt the architecture of PA biofilms was confirmed
by CLSM imaging, which was not observed when the biofilms of FRD1 were exposed to free
Tobra under the same conditions. The results shown here indicate that the developed and
patented dendrimer-Tobra conjugates represent new opportunities to overcome challenges of
existing Tobra formulations in treating bacterial biofilms in CF lungs. The relevance of this
study goes beyond the formulation of Tobra for the treatment of CF lung biofilms, as it may be
extended to other aminoglycosides and other classes of APIs relevant for the treatment of lung
bacterial biofilms that may also require shielding the strong interactions with extracellular
physiological environment including healthy and diseased mucus.
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2.6. Supplemental information
The characterization of the intermediates of the synthesis of G4OH-(Tobra) and G4OH-(Tobra)(PEG) conjugates including MALDI and 1H NMR. The release profile of dendrimer-tobra
conjugates roughly assessed by molecular weight (MW) measurement from MALDI-TOF is
shown. Representative images before and after fluorescence bleach in FRAP assay. Live bacteria
percentage (Live%) in FRD1 biofilm of negative control and all treatment groups for bacteria
viability (PI stain) assay is also provided.
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Chapter 3. In vitro dissolution methods for orally inhaled drug products:
challenges and opportunities
3.1 Introduction
In vitro dissolution testing has been well-established and routinely used to understand the
characteristics of drug products and set dissolution specifications for oral dosage forms as for
example in tablets and capsules [130]. It serves both as a quality control test to evaluate batch to
batch consistency of such drug products and as a useful tool to predict in vivo drug
pharmacokinetics (PK) profiles for immediate- and extended-release dosage forms [130][131].
Furthermore, dissolution is also required to assess bioequivalence (BE) and may be used to
waive in vivo BE studies of generic or modified drug products [132].
Orally inhaled drug products (OIDPs) have been widely used in local therapy for lung
diseases, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF),
and lung infections [133]. The major advantage of inhalation route of administration is that the
therapeutics can be delivered directly to the site of action, leading to fast responses and
potentially lower doses, as well as avoiding off-target toxicity [134][135]. There has been also
significant interest in achieving systemic effect upon pulmonary delivery of drugs given the large
surface area of the respiratory zone [136], less enzymatic degradation [137], no first past effect
and thus potential enhanced bioavailability [135]. For instance, inhaled insulin has been applied
in the treatment of type I and type II diabetes with FDA approval in US market [138-140]. The
most widely used device technologies of OIDPs consist of three major categories: pressurized
metered dose inhalers (pMDI), dry powder inhalers (DPI) and nebulizers [141-143]. Soft mist
inhalers have been more recently developed and approved by the FDA [144][145].
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Unlike common oral dosage forms, however, not only the formulations of OIDPs but also
the devices are integral to achieve efficient aerosol delivery to patients’ lung, and OIDPs are
classified as drug-device combination by the FDA [144]. Due to the complexity of OIDPs, their
in vivo performance is impacted by numerous factors including drug formulation, device
performance, and several patient-related factors [146][147]. These aspects not only work
individually, but also collectively to decide product efficiency [148]. Thus, the development and
evaluation of OIDPs are both very challenging. The total aerosolized dose delivered to the lungs
and the aerodynamic particle size distribution (APSD) are believed to be the most critical
parameters that affect the clinical safety and efficacy of OIDPs [149]. Consequently, the
delivered dose uniformity (DDU) and APSD testing are required by the FDA, being part of the
regulatory guidance for product characterization and quality assurance purposes [150][151]. The
cascade impactors are normally used to measure APSD, even though it is understood that they
are not good surrogates of human’s airways and cannot provide full prediction of the drug
pulmonary deposition [149].
Once the aerosol particles deposit on the surface of human respiratory system, the
subsequent drug absorption and bioavailability both depend on the drug dissolution that occurs in
the lung lining fluid (LLF) [152][153]. Meanwhile, certain clearance mechanisms compete with
the dissolution process in the LLF, including the mucociliary escalator that helps transport
undissolved particles up to the trachea, being subsequently swallowed and end up in the
digestive track, and macrophage uptake that happens in the alveolar region in which
macromolecules are typically degraded due to a pH drop from physiological condition to acidic
condition [154-156].
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In spite of the fact that dissolution plays a critical role in the fate of aerosol particles after
inhalation, including lung PK and systemic bioavailability, there is no existing pharmacopeia or
standardized method of dissolution testing of OIDPs [150][151]. Different from oral dosage
forms, FDA does not have any regulatory requirements for dissolution testing in the guidance for
industry to support the development of innovative or generic OIDPs [130][131]. Nevertheless, in
the FDA workshop “Regulatory Education for Industry: Advancing Innovative Science in
Generic Drug Development” in 2020, the FDA emphasized the importance of in vitro dissolution
testing in generic drug development and recommended to include dissolution testing as part of
alternative BE approaches when submitting ANDAs for OIDPs.
The purpose of this review article is to provide an overview of recent in vitro dissolution
methodologies developed for OIDPs, the suitability of different dissolution protocols and
existing challenges and opportunities in this area. The biopharmaceutical characteristics
influencing the formulation are also discussed under the context of deposition, dissolution,
absorption and clearance of drug particles in aerosols. Finally, the potential application of in
vitro dissolution testing from regulatory, research and manufacturing aspects are presented.

3.2 Deposition
3.2.1 Aerosol particle size and lung deposition
Typically, aerosol particles with aerodynamic sizes between 1~5 µm are regarded as
having optimal size for deposition in the deep lungs [157-159]. The majority of particles in the
fraction > 10 µm is deposited in the oropharynx due to inertial impaction and the fraction < 1 µm
reaches the alveolar region through browning diffusion, and can be also exhaled [160]. The fine
particle fraction (FPF) is defined as particles with mass median aerodynamic size (MMAD) < 5
µm, which is also the critical aerodynamic diameter for efficient delivery to the lungs [16].
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3.2.2 In vitro models to assess lung deposition
The in vitro assessment of OIDPs deposition in the lungs is done by characterizing the
DDU (Delivered Dose Uniformity) and APSD (Aerodynamic Particle Size Distribution) [162].
Standardized DDU and APSD testing for an inhaler device is required by FDA regulatory
guidance [150][151]. The most commonly employed aerosol characterization devices are the
Andersen cascade impactor (ACI), the multistage liquid impinger (MLI) and the next generation
impactor (NGI) [163]. These impactors are usually operated at fixed air flow rates (L/min) for a
period of time, and the flow rate is oriented for specific type of products. The mass of drug
contained at each stage (specific cut off aerodynamic diameter) is quantified by analytical
methods, and FPF and MMAD are determined by interpolation between stages [163].
However, in order to standardize the test and to obtain reproducible results with enough
discriminatory power, some realistic circumstances needed to be sacrificed in the design of the
cascade impactors [162]. The induction port of the impactor that connects to the inhaler unit, and
that is used to introduce aerosol particles to system is usually designed as a simple right angled
metal tube, which is also called “throat” [163]. As a surrogate, this United States Pharmacopeia
(USP) standard inlet does not bear enough anatomic characteristics to the human throat [163].
However, knowing the actual fraction of drug deposited in upper airway and the potentially
available drug deposited in lower airway can be critical to evaluate drug delivery efficiency in
real world applications, and to understand the impact of patient variability. A realistic APSD
should also provide a solid basis for the further dissolution testing [164]. Several more realistic
throat models have been developed, including Alberta idealized mouth-throat (AIT),
oropharyngeal consortium mouth-throats (OPC-MT) and the Virginia Commonwealth University
mouth-throats (VCU-MT) [165-170]. Meanwhile, not only the geometry of the “throat” impacts
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the assay, but also the patients’ breathing profile, affect the fine particle dose (FPD), which is
typically defined as particles with aerodynamic diameter < 5 µm [171]. For some DPIs, the
inhaled dose which could reach deep lung can be highly dependent on the respiratory pattern,
while MDI is less sensitive to variations in breathing profile [171][172].

3.3 Dissolution
3.3.1 Lung lining fluid (LLF)
Once aerosol particles deposit in the lung, they must dissolve in lung lining fluid (LLF) in
order to be absorbed by pulmonary epithelial cells [173][174]. Then the question becomes how
far drug particles can spread on the lung surfaces and how fast they can dissolve. Due to the
unique anatomy and complicated physiology of the respiratory system, the composition of LLF
varies due to the diverse pulmonary functional structures, and LLF composition can also be
impacted by the disease state [175][176].
Generally, human lungs can be divided into two different sections: conducting zone,
which includes trachea, bronchi, bronchioles and terminal bronchioles, and respiratory zone,
which consists of respiratory bronchioles, alveolar ducts and alveolar sac. The majority volume
of LLF is located in the conducting zone, covering the apical side of lung epithelium, and
characterized as a mucus gel layer [177][178]. This mucus layer has an estimated thickness of
10~20 µm and an approximate volume of 10~30 mL [179][180], with a pH close to neutral
(6.6~7.1) [181][182]. The mucus fluid can be further divided to two phases: top gel layer
possesses relatively high viscosity and elasticity, and the composition in healthy lung include
large amounts of water (~95%), crosslinked mucin (3~5%), inorganic salts (1%) and other
macromolecules such as protein and DNA; the bottom layer is called periciliary layer or sol layer
which mainly facilitates ciliary beating, as a rather watery solution phase [155][183]. Some
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researchers have pointed out that surfactant film contained in mucus layer will further reduce the
surface tension and enhance the wetting process, which consequently assist pushing particles
landed on the top of lining fluid downwards and sink into mucus blanket [184].
As most of the inhalers currently on the market deliver a solid or semi-solid form of
aerosol on the surface of mucus blanket, the PK of powder (DPI) and liquid formulations
(nebulizer and pMDI) with readily soluble drugs (eg. tobramycin and insulin) have been studied
[185-187]. Interestingly, under the premise of similar lung deposited dose, comparable PK
profiles were observed for powder and solution dosage forms on humans, suggesting that both
droplets and solid particles can be “dragged” down into mucus layer and this process should not
be a rate-limiting step [185-187]. If particles cannot be dissolved immediately, they will have a
chance to travel through the fluids and interact with other lung structures. Researchers have
observed intact aerosol particles in lung epithelial cells and systemic circulation after their oral
inhalation, suggesting that that paracellular and/or transcellular processes may play a role in the
drug PK in the lungs [189].
3.3.2 Clearing mechanism
The whole mucus layer acts as a protective barrier against inhaled particulates and
pathogens as discussed before [184]. Besides the mucociliary escalator that can help remove
whole particles from the airways, another important consideration is the pKa of the drug relative
to pH found in the mucus layer; solvated drug molecules bearing different charges in neutral pH
of the mucus can also lead to either repulsive or attractive force with mucin fibers, which also
affects the diffusion and residence time of the drug molecules. It is also important to consider
pH effect on disease state; for example, while healthy mucus has a pH of ca. 7.2, the pH of
mucus in CF patients is ca. 6.5 [189]. On the other hand, for lipophilic drugs like indomethacin,
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it has been reported that proteic and lipidic components of mucus can probably facilitate the
process of dissolution [190].
Before particles are cleared or fully dissolved, they may have the ability to penetrate the
mucus later. The mucus has a porous structure made of crosslinked mucin fiber, and particles
with a size lager than 500 nm may be “trapped” in mucus layer, while smaller particles may
diffuse through the mucus and reach the epithelial cells [191][192]. Nanoparticles as drug
carriers can thus be beneficial in enhancing penetration through mucus, depending on their
surface characteristics as they can also have strong electrostatic interactions with the mucus
mash through such non-bonded interactions [174]. For nanoparticles forming agglomerates, they
will either stay in the gel layer like micro-sized particles, or disperse into nanoparticles,
following by dissolution and partition into sol layer, depending on their aqueous dispersibility
and solubility [193].
At the same time, mucociliary clearance is one the most effective defense mechanism in
respiratory track. Secreted mucus continuously moves upward at a flow rate of 3~35 mm/min,
transporting undissolved particles to pharynx, which are subsequently swallowed [194].
Coughing is an effective method to promote mucociliary clearance, which has been
demonstrated diagnostic value in COPD [195]. Dissolution, mucus penetration and clearance are
competing processes that happen simultaneously and dictate bioavailability after aerosol particles
have been deposited in the lungs. Although the elimination of aerosol particles can be
determined by multiple factors, the residence time is strongly affected by these processes,
depending on whichever is faster. For micron-sized particles deposited on the top of airway
lining fluid, the faster they get solvated and dissolved, which usually requires a high aqueous
solubility, the better they can overcome mucociliary clearance.
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Comparing to the conducting zone, the surface of respiratory zone is relatively dry, but it
represents a much larger surface area of the respiratory tract by which drug molecules can be
cleared from the lungs. In healthy lungs, the thickness of airway lining fluid is < 0.1µm, with
high concentration of surfactants including phospholipids (80%), lipids (10%) and proteins (10%)
[155]. This layer is also referred as “epithelium lining fluid” (ELF). The commonly used in vitro
dissolution media usually have a similar composition to ELF. Considering the estimated volume
of ELF is around 20~36 mL, the small volume could set a limit on the dissolution rate for poor
water-soluble drugs [196-198]. Fortunately, the existence of surfactant can not only enhance the
drug solubility, but also reduce the fluid surface tension, promoting particle embedding in ELF
and preventing particle adhesion [174][184]. Unlike in conducting zone, particles that persist
without dissolution may be taken up by macrophages, which is the main clearance mechanism in
this zone of the respiratory tract, and is usually completed within 6~12h [199]. The uptake by
macrophages is size dependent. It has been reported that particles with geometric size ranging
from 1.5~3 µm are more likely to be engulfed, and sizes <1 µm or >5 µm have higher chance to
evade from macrophage uptake [200-202], but particles as small as a few nm in size such as
dendrimers and in the range of 100-200nm are also known to be efficiently taken up [203][204].
Surface coating with high density of PEG is another effective strategy to decrease but not
eliminate uptake in all cell types, including macrophage [205][206]. The microenvironment for
particles can dramatically change after internalized by macrophages. As contained in
phagolysosomes, pH drops down to an acidic values (4.5~4.8) from relatively neutral conditions
in ELF, and particles can be quickly disintegrated under such circumstances and drugs can be
degraded by digestive enzymes [155]. Meanwhile, macrophages from the alveolar region can
reach the lymphatic system in lung and subsequently accumulated in the lymph nodes [207].
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Once engulfed by macrophages, the half-life of particles is relatively long compared to that of
particles landed in conducting zone. The clearance can usually take days to months in humans
[199].
3.3.3 Factors that affect dissolution
Since the early stages of drug research development, dissolution has been established to
be one of main factors for drug bioavailability [208]. A well-established dissolution model can
also provide detailed information on how API dissolves at the site of action for absorption after
deposition. As discussed in Section 2.1, due to the complexity of lung anatomy and physiology,
we understand that simulating the lung environment can be very challenging. Also complex is
the fact that the critical physical properties of drug and formulation, for example, drug solubility,
delivered drug dose/mass, particle size and surface area, also greatly influence the dissolution
process. Thus, in order to design solid dissolution testing methods with predictability,
reproducibility and discriminatory power, the drug and formulation properties of inhaled
products should be considered in combination with the lung environment. The drug and
formulation factors will be discussed extensively next.
3.3.3.1 Drug solubility
In terms of physiological properties of the drug, the solubility is basically determined by
the physical form, lipophilicity, pKa and the pH of lung lining fluid [208]. The surfactant
contained in LLF can also enhance drug solubility [209]. For small hydrophilic molecules, the
absorption in lung is relatively fast, and reported to be within tens of minutes [155]. Even if the
dissolution media volume is small (LLF around 10~30 mL), the rate-limiting step for the
absorption is not dissolution, but rather permeation through the epithelial cells because of their
high solubility [210]. As bronchodilator, most of the inhaled short (SABA) and long-acting beta
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agonists (LABA) belong to this category. Since the dissolution does not critically affect in vivo
kinetics, the necessity of performing dissolution test for OIDPs with high solubility is also
questioned by FDA [175]. In contrast to LABA and SABA, because of the high lipophilicity,
inhaled corticosteroids (ICS) have a very low solubility in LLF, ranging from 0.13~140 µg/mL
[212]. In such circumstances, the LLF consisting of lipid and phospholipid-based surfactants can
lead to an increase in wetting, solubility and thus enhance the dissolution of ICS [213][214].
However, for extremely poorly soluble drug like fluticasone propionate, the dissolution process
and not cell membrane permeation becomes the rate-limiting step [215]. With respect to pKa, the
solubility depends on both solute and solvent. For instance, a weak acid will be prone to
deprotonate in LLF and there will be a higher fraction of deionized form than ionized form,
which could show a limited solubility in this case [223].
Solid state properties play an important role on the solubility [217]. Different
polymorphic forms, degree crystalline (amorphous content), solvate and co-crystals have been
explored to manipulate drug solubility and rate of dissolution [218][219]. It has been wellaccepted that for the same compound, amorphous form has higher water solubility than a
crystalline state, which can further result in a faster dissolution kinetics. To avoid unwanted long
residence times in lungs and consequent macrophage uptake, formulating poor aqueous soluble
drug into amorphous form is a potential strategy to accelerate dissolution and improve
bioavailability [220]. However, as amorphous state is less thermodynamically stable than
crystalline form, amorphous particles may recrystallize in contact with dissolution media [221],
leading to dissolution challenges.

77

3.3.3 2 Delivered Dose
The amount of dose delivered in the lung is also an important factor influencing
dissolution. Unlike bronchodilators and ICS (dose in µgs), inhaled antibiotics (eg. amphotericin
B and ciprofloxacin) usually require a high dose (in mgs) or high concentration in the site of
action to kill the bacteria. This may pose a limiting factor for the further absorption [84].
Meanwhile, by using in vitro dissolution models, it has been also demonstrated that undissolved
particles can slow down the dissolution process. Since the volume of LLF is very limited (10~30
mL), if particles accumulate at certain areas which exceed the saturation of LLF, a relatively
longer absorption time can be observed [215].
3.3.3.3 Particle size and other formulation factors
It has been identified that both geometric size and aerodynamic size of drug particle
influence the drug dissolution [215][222]. According to the Noyes-Whitney equation, the
dissolution rate should increase as the particle size decreases [223]. This is the most common
strategy to improve drug dissolution without altering or modifying the API. The other widely
adopted option is to formulate porous or hollow particles with low density and larger surface
area [223][224]. For example, the PulmoSphereTM technology has been applied to inhaled
tobramycin (TOBI® PodhalerTM) and other molecules to formulate porous particles in dry powder
dosage form [65]. Nanoformulation is another strategy.

One of the advantages of inhaled

nanoparticles is enhanced solubility, which can be explained by Ostwald–Freundlich equation
[225]. The smaller the particle size is, the higher the saturation solubility will be. Meanwhile, the
surface area is also increased, thus dissolution rate will be improved like conventional microsized particle [226]. On the other hand, agglomeration can be one of the challenges for
nanoparticles due to their large surface to volume ratio. To decrease the attraction forces between
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nanoparticles, some approaches have been proposed, such as addition of surfactants, utilizing
porous structure, and blending with carriers (DPI) to improve the performance for OIDPs
[193][227]. If nanoparticles aggregate into micro-sizes, then they need to dissociate after
deposition to proceed to further dissolution process [193]. Among various formulation factors,
the particles’ physio-chemical property also plays a critical role, which may be used not only to
increase drug solubility, but also affects the dissolution rate. For example, the alteration of
particle surface physio-chemical property caused by solution composition changing in pMDI
dosage form was observed. An increase of the ethanol content in the formation from 8 to 12%
(w/w) can retard the propellant evaporation, resulting in higher chance to form a smooth solid
particle surface and leading to a reduced dissolution rate for beclomethasone dipropionate (BDP)
[219]. Researchers have also shown that combining L-leucine or Colistin with azithromycin can
effectively increase the solubility and dissolution of hydrophobic azithromycin, suggesting that
changing formulation and surface composition is another potential strategy to enhance
dissolution [229][230].

3.4 Dissolution methodologies
3.4.1 Aerosol dose collection methods
It has been shown that there are significant differences between the bulk formulation and
an aerodynamically classified formulation in the dissolution profile [231][232]. Thus, the first
step towards dissolution testing is to collect appropriate amounts of particles which can be
applied in compendial or non-compendial dissolution setups. However, for inhaled products,
there is still argument on whether dissolution testing is preferred to perform only in respirable
range (aerodynamic size < 5 µn or FPF), which can simulate in vivo pulmonary situation to the
maximum extent and generate meaningful data to predict in vivo performance, or perform the
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assay on full range of dispersed aerosol particles or micronized formulations of API [232]. The
later collection method is relatively simple. The airbrush technique, aerosol generator (eg.
PreciseInhale aerosol generator), dry powder insufflators, and even manually spreading to spray
aerosol particles on membrane or glass/plastic-based slip have been employed [233][222][234].
To isolate aerosolized fine particle dose (FPD), the most common approaches include using ACI,
NGI or Twin-stage liquid Impinger.
In the earliest attempts to collect representative respirable samples without the fraction
deposited in the “throat”, filter paper was placed at the connection between the USP induction
port and the inlet stage of an ACI (stage 0) [235]. Although such method is claimed to maintain a
good particle dispersion and prevent agglomeration, disadvantages also exist. One potential
drawback is an overestimation of the inhaled fraction, as the collected samples actually include
pre-0 and 0 stage fractions, which usually have an aerodynamic size > 5µm. The typical dose
fraction separated by the ACI for dissolution testing is on stage 4 (cut off diameter at 2.1 µm
with 28.3 L/min flow) [215]. As full resolution ACI requires intensive labor and execution time,
abbreviated impactor (fast screening Andersen/FSA) are more frequently encountered in sample
collection step of dissolution testing [236][237]. The abbreviated impactor measurement (AIM)
model leaves off specific stages from the full-resolution ACI, still providing a relatively accurate
and precise collection of particles within defined size range (usually FPF <4.7µm) [238][239].
However, more recently, researchers realized that because of the thickness of filter paper placed
on that stage, the normal aerodynamic flow profiles, which has been validated for specific
devices, can be altered [232]. Furthermore, the particle distribution pattern will be affected due
to the even closer distance between the jet and filter paper [232][240]. Thus, a variety of
modified ACIs were developed to adopt specific requirements of aerosol particle deposition. For

80

instance, certain stages of ACI are displaced by cylindrical shaped extension (5.8 cm) or
customed hollow extension (2.6 cm) (Figure 3.1), aiming to favor a sedimentation rather
impaction of the fine particle deposition on collection stage [241][223][240]. Considering the
likelihood of particle agglomeration after impacting on collection stages directly under the air jet
in traditional ACIs, the collection stage has been also modified, consisting of three small bars
(Fig 3.1). This approach has the advantage of dispersing aerosol particles over a larger surface
area, creating a well-dispersed and uniform particle layer. As the particles need to disassociate
from any agglomerates to proceed with pre-defined dissolution profile, and undissolved dose can
impact dissolution rate, when a large mass is loaded, as discussed in 2.2.2, this modified ACI
(mACI) can help mitigate the unwanted impact brought by particle agglomeration in dissolution
tests later on.
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Figure 3.1 Schematic drawing of abbreviated ACI with extension, normal filter stage or
modified filter stage.
NGI is another widely accepted device to separate aerosolized FPF. Similar to ACI, membrane
filters are placed in certain plates/cups to collect the desired particle fraction. Stages 3, 4 and 5
are commonly used [231][229][242]. One consideration for NGIs is how to adapt the filter paper
in NGI cups and ensure a suitable incorporation with subsequent dissolution devices. At the very

beginning, the filter membrane is placed under a pre-trimmed wax paper with rectangular
uniformly sized holes (2 cm × 2.5 cm) to keep the same exposure area on each plate (Fig 3.2). A
membrane cassette is used as sample holder in the dissolution apparatus [231]. However, it is
rather inconvenient to cut filter paper. A modified NGI cup with a removable impactor insert
together with stainless steel filter has been developed to overcome such issues [242]. This
commercially available cup is well adapted in NGIs and can be directly transferred to the
dissolution setup. This is a significant improvement towards practicality and a time saver. It also
provides easy comparison of dissolution profiles of different products within the same size range,
minimizing manipulation error. Another benefit could be avoiding mass loss during the
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transferring process, which is a potential source of variability in the subsequent dissolution tests
[243]. However, like traditional ACI, the removable insert does not resolve the problem of the
altered particle deposition pattern and particle agglomeration. A more recent aerosol dose
collection (ADC) system named as UniDose was designed to address some of those issues. ACD
is incorporated in the stage 2 of NGIs (Fig 3.3) [104]. It has been validated that the whole
impactor stage mass (ISM) can be homogeneously distributed on a collection membrane surface.
In the subsequent dissolution test, dissolution rate was demonstrated to be less sensitive to
loading mass factor, and an increase in robustness and discriminatory power of different particle
size was observed [213].
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Twin-Stage Impinger (TSI) is also used in the sample collection step, though not very
common. Basically, as TSI can roughly separate coarse (aerodynamic size >5 µm) and fine
particle fractions, a membrane filter pre-soaked with dissolution medium is placed in the lower
chamber to collect sample [219][244]. Still, a similar disadvantage of TSI is that the lower air jet
is located very close to the membrane filter, possibly causing the formation of a thick particle
layer which leads to particle agglomeration.
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In order to avoid some of the drawbacks as described above and save execution time, a
Fast Screening Impactor (FSI) based on NGI preseparator technology was developed [245]. FSI
can readily separate the dose into Coarse Particle Mass (CPM) and Fine Particle Mass (FPM). A
collection plate incorporated with filter membrane is set below the outlet of impactor housing.
The fine particles are be captured directly on the membrane, and easily transferred to dissolution
apparatus [246-248].
Cell culture inserts of air-liquid (ALI) grown cell models can be integrated to the
UniDose system, thus resulting in a cell-compatible NGI, which allows direct deposition of
aerosol particles on cell monolayer (eg. Calu-3 cells) [249]. Another physiological impactor
system named as Pharmaceutical Aerosol Deposition Device On Cell Culture (PADDOCC)
collects particles within 2~5 µm to deposit on relevant cell culture (ALI) grown on transwell
inserts. This device is also integrated with particle sedimentation as deposition mechanism [250].
The development of such cell culture related impactor system allows for the investigation of the
interplay of in vitro deposition, dissolution and absorption of OIDPs combined.
3.4.3 Dissolution apparatuses
In general, the dissolution apparatuses used for OIDPs can be divided to three groups,
namely, compendial paddle/paddle disk apparatus (USP II/V), modified flow through cells (USP
IV) and diffusion-controlled cell systems (Franz cell and Transwell insert system). The usage of
dissolution apparatus and dose collection methods, regarding different inhalation products are
summarized in Table 3.1. In Figure 3.4, USP apparatus I to VII, and two other commonly used
OIDPs dissolution apparatus are illustrated. Other less frequently used apparatuses will be also
discussed below.
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Table 3.1 Dissolution methodologies for some OIDPs reported in publications.
Product

API

QVAR (pDMI),
VANCERIL (pMDI)

Beclomethasone
dipropionate (BDP)

FLOVENT HFA (pMDI),
FLOVENT
DISKUS (DPI)
PULMICORT
TURBUHALER (DPI)

Fluticasone propionate
(FP)

AEROBID (pMDI)
AZMACORT (pMDI)
AEROBID (pMDI)

All same product as
reference 8

Alvesco, Symbicort,
Flixotide (GSK HFAMDI)
Budesonide micronized
particle in PE capsule
(HandiHaler® DPI)
Fenoterol micronized
particle in PE capsule
(HandiHaler® DPI)
Budesonide micronized
particle in PE capsule
(HandiHaler® DPI)
Micronized Budesonide,
fluticasone furoate and
fluticasone propionate,
using Screenhaler (DPI)
with Turbuhaler
mouthpiece
Flixotide Accuhaler®
(DPI), Pulmicort
Turbuhaler® (DPI),
Azmacort® (metered dose
DPI)

8 stage ACI, PVDF filter
membrane membranes
placed on stage 4

Budesonide (BD)
Triamcinolone acetonide
(TA)
Flunisolide (FN)

AZMACORT (pMDI)

Aerosol Particle
Collection

8 stage ACI, assembly
modified, NC membrane
placed on stage 7
8 stage ACI and NGI,
glass fiber membrane on
stage 4

Ciclesonide, BUD,
Flixotide (FP)
Budesonide

Abbreviated ACI,
cellulose membrane

Fenoterol HBr
Modified aACI with a
stage of 5.8 cm
cylindrical shaped
extension, RC membrane

Budesonide

Dissolution
Apparatus

Transwell dish

Reference

215

Transwell dish

237

Transwell dish

255

Flow through
cell, Modified
Franz cell,
Paddle disk

236

Paddle disk

Budesonide, fluticasone
furoate (FF) and
fluticasone propionate
(FP)

Modified ACI

Budesonide, fluticasone
propionate, triamcinolone
acetonide

Modified ACI+USP
induction port

Micronized hydrocortisone
w/wo lactose as carrier,
using Aerolizer® (DPI)

Hydrocortisone (HC)

NGI, PC membrane
placed on stage 3,5

Modified
paddle disk

231

Co-spray-dried
Azithromycin with Lleucine

Azithromycin (antibiotics,
but still poor solubility)

NGI cellulose filter paper
on stage 4

Modified
Franz cell

229

86

Transwell
dish,
Apparatus 2
(paddle disk)

241

Modified flow
through cell

223

235

Budesonide &
montelukast + lactose as
carrier, Aerolizer® (DPI)

Budesonide &
montelukast

Ventolin
HFA, Pulmicort Flexhaler

Albuterol

Flixotide® Evohaler®
(MDI), Flixotide®
Accuhaler® (DPI),
Seretide® Accuhaler®
(DPI), Relvar® Ellipta®
(DPI), Asmanex®
Twisthaler® (DPI)

fluticasone propionate
(FP),
salmeterol/fluticasone
propionate combination
(S/FP), fluticasone furoate/
vilanterol combination
(FF/V), mometasone
furoate (MF)

QVAR, Sanasthmax (both
solution pMDI)

beclomethasone
dipropionate (BDP)

Qvar, Foster, Clenil
Modulite, BDP Extrafine
(investigational product)
(all solution pMDI)
Budesonide and
fluticasone aerosolized
with PreciseInhale

NGI stage 4

Franz cell

Modified NGI with a
dissolution cup

USP apparatus
2 (paddle
disk)

Aerosol Dose Collection
(ADC) System,
incorporated with NGI
stage 2

USP apparatus
V (paddle
disk)

Modified TSI (Twinstage Impinger)

218

242

213

Franz cell

244

beclomethasone
dipropionate (BDP)

Modified TSI, PC
membrane placed in
lower chamber

Franz cell

219

BUD and FP

DissolvIt

an air-blood
barrier model

216, 264

USP paddle apparatus
The paddle dissolution apparatus is used in paddle over disk mode. USP apparatus II has
been widely used in standardized in vitro dissolution testing for solid dosage forms (e.g. tablets).
Thus, there is no original “disk” available in the setup. The advantage of this approach for OIDPs
is the convenient adaption with different types of aerosol particles collection filters, including
home-customized holders. For instance, a modified histology cassette was applied instead of
“disk” [231]. The polycarbonate filter membrane is pre-cut to a rectangular shape and placed in
NGI cup to collect aerosol particles. As histology cassettes are designed as an enclosed
membrane holder, this system shows high reproducibility and low variability [231]. Contrasting
to the histology cassette, people designed a new setup composing of an NGI cup and a
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removable impaction insert, which is a more convenient and practical approach (Fig. 3.5) [242].
Generally, after aerosol particle deposition, the removable insert is covered with a pre-soaked
filter membrane to retain the particles on collection surfaces and sealed with a securing ring. This
membrane holder “sandwich” is directly dropped into the dissolution vessel to initiate testing.
Unlike apparatus II, USP apparatus V contains both paddle and disk. The disk is usually made of
glass or metal piece, together with a mesh cover [107][108]. The commercially available watch
glass and polymeric mesh screen are readily used to hold filter membrane with aerosol particles
[213][222][236][241]. The filter membrane can be placed on watch glass with collection surface
facing down and clamped together with the mesh screen.
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Figure 3.4 An overview of methods that have been used for testing of formulations for oral inhalation.
Basket (apparatus I), paddle (apparatus II), reciprocating cylinder (apparatus III), ﬂow-through (apparatus
IV), paddle over disk (apparatus V), cylinder (apparatus VI), reciprocating holder (apparatus VII), Franz
cell, and Transwell system.
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Figure 3.5 Modified NGI dissolution cup (left) and Stainless steel filter placed above stage 3 of NGI.

One of the challenges in using paddle disk apparatus is the setup for the collection of
aerosol particles. On one hand, introducing an extra retaining filter membrane can reduce the
mass loss during sample transfer. On the other hand, this filter membrane may act as a barrier for
particles to be wetted and an extra layer to diffuse through. This scenario also applies to watch
glass-collected particles-membrane filter model in USP apparatus V. Either way, the drug release
from membrane holder becomes a dissolution-diffusion-controlled process. As the dissolution
media migrate through membrane filter, the dispersed drug inside the membrane undergoes
dissolution. Then the dissolved drug is released outside the membrane filter by diffusion and
quickly removed from the membrane surface under sink-condition. In an ideal scenario, the
dissolved drug should freely diffuse through the filter membrane and apparent dissolution rate
should not be override by the diffusion rate. In other words, diffusion should not become the
rate-limiting step. This barrier effect can be minimized by 1) optimizing the properties of
membrane such as the type of material, pore size, pore tortuosity, and membrane thickness, 2)
adding surfactant to improve the wettability of dissolution media [231][242]. Some research has

90

pointed out that thin Isopore polycarbonate (PC) membrane filter is suitable for the dissolution
testing of poorly soluble inhaled drug (e.g. budesonide) in aqueous media [240].
The volume of the dissolution media for paddle disk apparatus can be easily adapted to
different dissolution cases, for example, sink conditions mimicking fast dissolution/absorption
and non-sink conditions with limited volume of media simulating slow dissolution. Vessels in
different volumes are commercially available (eg. mini vessel as 150 mL and normal vessel as 1
L) [231].
Flow through cells apparatus
The current flow through cell systems used for the dissolution of OIDPs are originated
from USP apparatus IV, sometimes referred to as modified USP apparatus IV [251]. For
dispersed systems (e.g. suspensions and powders), mixing sample with glass beads (about 1 mm
diameter) has been reported when applying standard apparatus IV, which can help hold the
sample and prevent powders descending into the inlet tubing [252]. However, this method is
difficult to apply to pre-isolated aerosolized particles, especially for fine particles, which are
usually collected on the surface of membrane filters and sandwiched with another membrane as
described in USP paddle apparatus. Instead, a modified flow through cell for OIDPs typically
contains two extra stainless-steel filters to hold the membrane filter sandwich [235]. The
dissolution media is pumped through the flow cell from bottom to the top by means of a high
performance liquid chromatography (HPLC) pump. Most particle filter approaches to
aerosolized sample collection can be made to work with flow through cell system
[235][236][253].
The flow through cell system provides a significant advantage as one can achieve
permanent sink condition by continuously flowing dissolution media through sample sandwich,
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which is suitable for poor soluble drugs. Two operation modes, open and closed, can be adapted
either for low solubility compounds which need high volume of media (open system) or samples
requiring a limited media volume (closed system) [251]. The flexibility of changing flow rate,
temperature and even dissolution media within one test run is another benefit. However, it is
important to consider the fact that they can lead to nonhomogeneous “agitation” conditions
within the cell, resulting from their flat geometry. In contrast to the high fluid velocity flowing
through the center of filter membrane, the flow rate can be relatively low towards the boundary
area, which potentially creates non-sink conditions locally [232]. Consequently, dissolution
becomes a diffusion-controlled process. Under such circumstances, increasing flow rates can be
an option to overcome this issue, converting dissolution to a flow-rate controlled process [240].
The other issue introduced by the device geometry is the air bubble entrapment, which can
possibly prevent membrane wetting and dissolution process.
Diffusion controlled cell system
The commonly used diffusion controlled cell include modified Franz cell and Transwell ®
system. The filter membrane deposited with aerosol particles on the surface is placed on top of a
dissolution media reservoir (acceptor compartment). The donor chamber usually contains zero or
very little amount of dissolution media, while the media in acceptor chamber can vary from a
few mL to 1L [232]. Compared to the flow through cell and paddle disk system, the diffusion
controlled cell system without agitation represents static conditions, which is considered as a
more biorelevant simulation of in vivo situation in the lung [215]. However, in some scenarios,
as to fulfill the requirement of homogeneous sink conditions, agitation needs be maintained by
placing stirring bar in acceptor chamber or surfactant can be added in the dissolution media,
especially when there is only limited volume of fluid in acceptor chamber (eg. the wells in
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microplate to hold transwell inserts only have a capacity of 1.4 ~10 mL) [218][229][244][255].
With the particle collection surface facing towards the transwell insert membrane, this approach
successfully creates an air-liquid interface, which better represents the realistic in vivo situation
in lungs. However, one still needs to bear in mind that the drug diffusion through the filter
membrane is far from in vivo conditions [237]. Typically, the semipermeable membranes of
transwell inserts are believed to mimic the air-liquid interface of the epithelial lung wall and the
drug molecules need to diffuse through it after dissolution. Therefore, it is critical to distinguish
the diffusion rate and the actual dissolution rate, especially only dissolution rate is interested
[232]. To directly compare dissolution rates for different drug products, the affinity of the
compound to the membranes and the diffusion coefficient are necessary before the dissolution
testing [240][265]. Basically, a high diffusion coefficient and low retention through filter
membrane are required when choosing membrane materials, so that the diffusion process will not
become the speed-limit step [232][240]. A modified Transwell ® system has been proposed in
which the original polycarbonate membrane from the transwell insert is removed. In such way, it
allows direct replacement of the filter membrane deposited with aerosol particles after sample
collection with ACI or NGI [255]. In this case, filter membrane can be placed with particle
collection surface facing up. Initiation of dissolution testing by adding very small amounts of
media (40~100 µL) in donor chamber has also described in the literature [237][255]. However,
this may lead to the interruption of air-liquid interface formed in donor chamber. Furthermore,
the thickness of liquid layer in donor chamber (80~200 µm) is much higher than that of the real
LLF (10~23 µm).
Compared to Transwell® system, one disadvantage of Franz cell is the possibility of
introducing air bubbles under filter membrane, or wrinkles on the membrane itself [236]. Both
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phenomena will lead to inhomogeneous membrane and particle wetting, which is a common
source of high variability in obtained data. Therefore, extra caution needs to be taken when
inserting samples between donor and acceptor compartments.
Finally, aerosolized particles can be directly collected on the Transwell inserts. As
described in Aerosol Sample Collection section, UniDose system was integrated with Calu-3
cells grown on transwell insert to develop a model combining dissolution and absorption [249].
This system can be easily adapted in dissolution testing without growing cells, which represents
a labor and time-saving approach.
Other systems
A novel system called DissolvIt® was designed to simulate the in vitro process of
dissolution and absorption at the same time [216][264]. An air-blood barrier model was
assembled with a membrane covered with artificial mucus on one side and a constant flow of
blood simulate perfuse along the other side. A glass cover slip deposited with aerosol particles is
placed upon the air-blood barrier model, with the collection surface facing the mucus layer.
Dissolution samples are analyzed by collecting blood simulate exiting the dissolution cell.
Meanwhile, the behavior of particles can also be visualized by microscopy. This method is both
diﬀusion and ﬂow-rate controlled.
3.4.4 Dissolution media
Dissolution media is another critical factor in the in vitro dissolution test for OIDPs. The
composition of dissolution media varies from simple phosphate buffer saline (PBS) based
solution to rather complicated simulated lung fluids (SLF). The choice of dissolution media
strongly depends on the study aims and the products’ physiochemical properties. For example, a
biorelevant fluid containing phospholipids and proteins, which mimics the natural environment
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in the lung fluids, is usually used in development stage or the investigation of media’s effect on
dissolution rate [235]. On the other hand, simpler dissolution media only including water, salts
and a few kinds of natural or synthetic surfactants are usually preferred in routine quality control
tests in industry [265]. Simple dissolution media are cheap, easy to prepare, capable of producing
data with high reproducibility and does not require extra effort in the subsequent method
establishment for sample analysis as for example HPLC [266].
Pulmonary surfactants in epithelial lung fluid (ELF) is a complex mixture of
phospholipids and proteins, among which phospholipids is about 70~80%, mainly
dipalmitoylphosphatidylcholine (DPPC), protein about 10% and neutral lipids about 10%,
mainly cholesterol. As DPPC is the most abundant lung surfactant, both simple dissolution
media and SLF frequently include DPPC (0.01~0.05% w/v) in the recipe, particularly in analysis
of poorly water soluble drugs [231][235][237][241][242]. However, the preparation of DPPC
solution is difficult and time-consuming, usually involving organic solvent dehydration and
aqueous solvent rehydration steps [242]. Moreover, due to the low critical micelle concentration
of DPPC (0.46 nM at 20˚C), micelles are highly likely to be formed in dissolution media, which
may clog the pores on filter membranes [228][254]. Therefore, synthetic surfactants, such as
sodium dodecyl sulfate (SDS) and Polysorbate 80 (Tween 80), have also been commonly used in
in vitro dissolution test, sometimes for comparison with dissolution media without surfactant
[213][219][222][228][242][255]. Surfactants are added to improve the wetting of membrane and
the surface of deposited drug particles, and are thus expected to alter dissolution rates. The
addition of surfactant also increase solubility [269], a 200~3000 fold of solubility enhanced may
be seen upon addition of 0.5% SDS in PBS as compared to unmodified PBS for FP (fluticasone
propionate) and CIC (ciclesonide) [255]. However, it is questioned whether such dissolution
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media are relevant to describe the in vivo milieu, and whether the model still maintains enough
discriminatory capacity to differentiate various products and formulations.
The pH of dissolution media typically falls around 7.4. One exception is artificial
lysosomal fluid (ALF, pH=4.5), which particularly simulate the fluid with which inhaled
particles come in contact after uptake by alveolar macrophages in the lungs [266]. Although
SLFs are generally more physiological relevant media, the complex compositions occasionally
result in a lack of buffering capacity. Thus, they may not be suitable for the API/formulation
which is sensitive to pH alteration nor sustained release dosage form. It has been observed that a
pH of SLF increased from 7.4 to 8.8 in 24h with dissolution of budesonide [242]. Continuously
bubbling CO2 through the media may help to overcome this issue [270].
The volume of dissolution media is another controversial topic in the dissolution practice
of OIDPs [215][175]. Conventional dissolution testing for oral dosage form products requires the
maintenance of sink conditions. For sink conditions, as defined by the FDA, the concentration of
drug in the media at 100% release should not exceed 1/3 of the saturation concentration [130].
However, due to the limited fluid volume (10~30 mL) in the lung, it appears to be challenging
for “insoluble” drugs to dissolve under sink conditions even considering the low doses of
pulmonary administered drug. For instance, the dissolution profile of certain poorly soluble ICSs,
including fluticasone propionate (FP), beclomethasone dipropionate (BDP), mometasone furoate
(MF) and ciclesonide (CIC) were kinetically characterized as pseudo zero order in 10 mL
volume of dissolution media (LLF) with only around 50% drug release at endpoint, suggesting
the existence of non-sink condition at 9h of experiment initiation [237]. In contrast, ICSs with
high to intermediate solubility, for example, budesonide (BD), triamcinolone acetonide (TA) and
flunisolide (FN), show first order dissolution profiles and almost completed drug release in the
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same volume of dissolution media, indicating that the inhalable fraction of these drugs
underwent dissolution in a sink condition [237]. It seems that the application of sink and nonsink condition strongly depends on the solubility of API in the products. However, for some prodrugs, such as BDP and CIC, the sink condition can actually be maintained because of their rapid
hydrolysis upon dissolution, which in turn facilitate the active drug dissolution [211][271].
Therefore, the bio-relevance of sink and non-sink conditions in dissolution testing for OIDPs still
requires further clarification.
3.4.5 Other factors influencing dissolution
Usually, aerosolized particles are collected on filter membranes via impaction or
sedimentation prior to dissolution. A variety of membranes prepared with a wide range of
materials, diameters and pore sizes have been applied in in vitro dissolution studies of OIDPs. As
described previously, the diffusion of drug molecules through the filter membrane may have an
impact on the kinetics of the final dissolution profile because of the potential interaction between
dissolute and membrane [272]. Although the pore size of filter membrane is usually large enough
(0.1~3 µm) for API molecules to pass through, the affinity of the substance to certain membrane
material is still a critical factor, which can determine whether the diffusion process will become
the rate-limiting step in dissolution tests, and how much substance will be retained finally. For
example, researchers have demonstrated that polyester (PE) membrane showed slower diffusion
for BD than Isopore polycarbonate (IPC) membranes and regenerated cellulose (RC) membrane
[272]. For PC membranes, around 80% of BD diffused through membrane in 4h, whereas less
than 30% substance diffused through transwell PC membranes in the same time period,
suggesting a much lower permeability of transwell PC membrane than IPC membranes [240].
Therefore, considering the retained drug fraction on the collection filter membrane, it is
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necessary to wash out membrane with extraction solution at the endpoint, which can contribute
to the total mass recovery in dissolution testing. Finally, a smaller pore size (0.1~0.4µm) should
be chosen as larger porous structure (eg. 3 µm) may allow a direct permeation of undissolved
aerosol particles into dissolution media, particularly for the particles with geometric size <3 µm
[237].
Since the lung fluid is much more stationary in comparison to gastrointestinal fluids, the
high velocity of fluid in diffusion-through cells and agitation in USP apparatus may not reflect
the actual in vivo dissolution process of deposited aerosol particles. However, in real dissolution
testing practice, a faster dissolution rate was achieved by introduction of agitation/stirring,
together with a higher reproducibility than unstirred model, which provided a time-saving
manner and high-quality data [240][272]. Appropriate agitation is particularly important to
ensure good consistency when using paddle disk model (USP apparatus) due to the large volume
of dissolution media (usually 1L vessel) [213][222][236][241][242]. Irregularly moving of
sample disk was observed with high stirring speed (>150 rpm) [240].
The temperature and humidity in dissolution testing should also be within the
physiological relevant range. The temperature of inhaled air in respiratory tract is between
32.5~33.5˚C, varying with air flow rate [273]. However, 37˚C is commonly used temperature in
in vitro dissolution study [175]. Humidity at 100% is usually maintained when employing
Transwell® insert system, which also prevents evaporation of dissolution media.

3.5 Regulatory perspective and potential application of in vitro dissolution testing
for OIDPs
Despite the potential impact of dissolution profile on local lung and systemic PK and
subsequent therapeutic effect of OIDPs as discussed earlier, there is no regulatory requirements
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for in vitro dissolution testing for OIDPs in FDA statements [274]. An Ad Hoc Advisory Panel
of the US Pharmacopeia discussed the importance and necessity of developing dissolution testing
for OIDPs in 2008. However, due to a lack of standardized methods and well-established
relationship between in vitro dissolution and some parameters of bioavailability for inhaled
products, the panel suggested that it was still premature to concern the compendial dissolution of
inhalation dosage forms. Nevertheless, they reinforced the importance of dissolution testing as a
future need in novel or generic OIDPs development and quality control by industrial
development or regulatory concern [70][97]. However, since 2008, more in vitro dissolution
models utilizing compendial and/or non-compendial apparatus have been developed.
Discriminatory capacity was also demonstrated in some of these models for different OIDPs [79][12][111]. Given the complexity of OIDPs, the in vitro dissolution tests could be used as
promising tools for formulation development as quality assurance tests.
Current advancements in the various approaches to establish BE for generic locally acting
OIDPs is, on the other hand, a different scenario. After FDA’s systematic efforts on the
investigation of the relevance between in vitro testing and BE establishment, the importance of
in vitro dissolution testing started to become clearer. The traditional approach to BE
establishment for OIDPs is a weight of evidence procedure, including in vitro BE studies, PK BE
studies and comparative clinical end point (CCEP)/pharmacodynamic (PD) BE studies. The
challenges surrounding CCEP or PD BE studies are very clear. Unlike PK data, which is usually
generated from healthy subjects, the high variability of CCEP studies, which is associated with
various patients’ disease conditions, can lead to lower accuracy and reproducibility in subsequent
BE establishment [123]. In addition, a flat dose-response curve was observed in the study of
inhaled salmeterol (DPI and pMDI) utilizing bronchodilation PD model [125][126]. These
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inadequate dose-response relationships would also result in low sensitivity for BE studies.
Therefore, FDA raised the possibility to explore alternatives to CCEP/PD studies to facilitate
more accurate, sensitive and reproducible methodologies in BE establishment [123]. The
potential alternative approaches should address 1) the relationship between the regional lung
deposition level of inhaled drug and the time-dependent drug plasma concentration (systemic PK
data), 2) the correlation between in vitro performance and in vivo drug deposition. If successfully,
the CCPE/PD study may not be needed in the weight of evidence approach, without
compromising the efficacy and safety of proposed generic OIDPs [123]. To assess the
relationship between regional drug deposition in the lung and local/systemic PK profile, it is
critical to understand how API dissolves at the site of action for absorption upon deposition. The
dissolution data can be used to establish in vitro-in vivo correlation (IVIVC). Therefore, FDA
encourages companies to perform dissolution testing as part of the alternative BE approach, in
addition to the traditional in vitro testing, which is predominantly based on APSD related tests.
In the European Union, in vitro dissolution testing for inhaled fraction is not required either
[126]. As a relationship between dissolution rate and appearance of drug in plasma has been
reported, the biowaiver criteria apply to the OIDPs containing drugs that can be biowaived
according to the Biopharmaceutics Classification System (BCS) based on dissolution profile
comparison [126][127].
In the actual regulatory practice in the US, the dissolution method is recommended to be
validated, discriminatory and reproducible from the FDA perspective [153]. The ideal
dissolution study should be able to capture the differences in formulations, even though similar
aerodynamic properties has been observed [274]. Specifically for poorly soluble OIDPs, a
predictable dissolution model is recognized as valuable asset. A successful dissolution model
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should be able to correlate dissolution half-life (t1/2) and mean absorption time (MAT), when the
dissolution is the rate-limiting step for drug absorption upon pulmonary deposition [213]. Recent
studies about the relationship between in vitro dissolution rate and in vivo PK in rat model have
been reported [275]. The in vivo dissolution rate was obtained by deconvolution from drug
plasma concentration. The authors were able to establish a Level A IVIVC equation and
successfully predict the in vivo performance according to their formulation with different
particles sizes, suggesting the possibility of utilizing this model to screen desirable formulations
of the same API. The correlation between in vitro dissolution profile and in vivo PK data also
facilitates the approval of different strength and post-approval changes in formulation
development and manufacturing process based on dissolution data, which is beneficial in
reducing regulatory burden and unnecessary extra human studies in generic product development
[132].
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Chapter 4. Conclusion and Future work
Microbial biofilms are ubiquitous in nature [256]. Bacterial biofilms are the root cause of
many chronic infections, such as in teeth, urinary tract, middle ears and chronic wounds.
Bacterial biofilms formed on implants and catheters also give rise to opportunities for infections
related to medical devices. Due to the dysfunction of CFTR, CF patients usually suffer the
accumulation of mucus in their lung, which provides an optimal microenvironment for bacterial
infection and the further formation of biofilms [256]. Such chronic bacterial infections typically
result in inflammation, and gradually impact lung tissue function. The resulting respiratory
failure is the most common cause of death in patients with CF. Unfortunately, P. aeruginosa,
which is usually the dominant species colonizing CF lungs, adapts to the respiratory zone and to
the innate and adaptive defense mechanisms of the lungs by forming the mucoid biofilms [98]. P.
aeruginosa in biofilms also adapts to aggressive antibiotics therapy and anaerobic conditions by
developing both conventional resistance mechanism and biofilm related resistance [20]. Novel
drug delivery approaches, are thus required to help overcome these drug resistance mechanisms,
and to bring hopes of eradication of such persistent infections. Nanocarriers such as polymeric
nanoparticles, liposomes, solid lipid nanoparticles, have been proposed as strategies to address
some of the drug resistance mechanisms discussed earlier [48].
We are particularly interested in dendrimer-based nanoplatforms that can used to address
biofilm resistance and deliver therapeutic molecules by precisely modifying the surface
properties of the nanocarriers. Firstly, we demonstrated that shielding the charge on the surface
of dendrimer nanocarriers can improve their distribution and penetration in biorelevant matrices.
More specifically, we designed stealth nanocarrier-therapeutic molecule conjugate systems that
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can modulate drug interaction with the physiological environment, and explored the
effectiveness of the proposed strategies using well-accepted in vitro biofilm models.
In this work, generation 4 polyester dendrimer (G4OH) was used as nanocarriers. We
first converted the surface -OH groups to amine groups (-NH2), which served as a good mimic of
the functional group of tobramycin, a drug molecule of clinical relevance and interest in CF P.
aeruginosa treatment. We demonstrated that high density of PEG can shield the charge of such NH2 on the surface of G4OH. The resulting neutral surface charge promoted the penetration and
diffusion of dendrimer conjugates in bacterial biofilm and synthetic mucus model, which are the
two main physiological barriers that prevent therapeutic molecule from reaching their site of
action. A P. aeruginosa biofilm model growing under continuous flow conditions in flow
chamber was used in the proof-of-concept experiments. Based on this demonstration, we
developed a new dendrimer-based antibacterial formulation, by conjugation tobramycin to
G4OH and/or corresponding dendrimer modifications with PEG to achieve both positively
charged (G4OH-(Tobra)) and neutral (G4OH-(Tobra)-(PEG) ) dendrimer drug conjugates.
Tobramycin was conjugated to G4OH via a hydrolysable covalent bond. The antimicrobial
activity of free drug and dendrimer-drug conjugates were firstly tested against planktonic
bacteria, employing the standard protocol of MIC measurement. The accelerated release of the
drug was performed under basic conditions. The MIC of hydrolyzed products was shown to be
comparable to free tobramycin, suggesting that the bioactivity of conjugated therapeutic
molecule was well maintained. At the same time, G4OH-(Tobra) and G4OH-(Tobra)-(PEG)
conjugates exhibited almost 32~64 times less inhibition efficiency on P. aeruginosa in its
planktonic phase within time frame shorter than required for full drug release, indicating release
tobramycin release critical to drug activation. In antibiofilm studies, a static biofilm in vitro
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model grow in 96-well plates was established with G4OH-(Tobra)-(PEG) suppressing the growth
of P. aeruginosa biofilm to a much lower degree than free tobramycin and G4OH-(Tobra) at
relatively higher concentration (8 and 16 µg/mL), together with a longer treatment time period
(48h).
Interestingly, a similar trend was also observed at 24h, but without a statistically
significant difference, suggesting a possible extended release of tobramycin from dendrimer
conjugates under the microenvironment of PA biofilm, especially in mucoid strain. Meanwhile,
the strong ability of G4OH-(Tobra)-(PEG) to destroy the architecture of P. aeruginosa biofilm
was confirmed by CLSM images, while free tobramycin treated group did not lead to biofilm
destruction under the same circumstances. The developed dendrimer drug conjugates with
appropriate surface modifications represent a promising new direction in overcoming bacterial
biofilm resistance for CF therapies. The clinical and scientific relevance of the study on surface
PEGylation effect goes beyond the formulation of tobramycin. Other API molecules with
positively charged functional groups have similar potential to be formulated in conjugates similar
to the ones discussed here.
It is also critical to understand the biofilm formation process in the human airway, and
new biorelevant in vitro models are critical for screening new formulation strategies [257][258].
Once such models are well-established and validated, they can also help reduce the burden of
animal experiments and potentially shorten preclinical trials [257]. Thus, we explored the
possibility of establishing an in vitro bacterial biofilm an mammalian in vitro co-culture model,
by combining human pulmonary epithelial cells (Calu-3 and CFBE41o -1) and P. aeruginosa
(mucoid strain). Calu-3 is a human lung cancer cell line and displays epithelial morphology,
which produces mucus when cultured under proper in vitro conditions. CFBE41o-1 is an
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immortalized CF cell line, that lacks mucus prouction. The two cells were cultured in transwells
inserts under both air-liquid interface (ALI) and liquid-covered culture (LCC). The formation of
monolayer was demonstrated by cross sections (Fig 4.1) and barrier properties were assessed by
measuring transepithelial electrical resistance (TEER). As shown in Fig. 4.2, the TEER value of
Calu-3 reached plateau around Day 10 after seeding and CFBE41o -1 around Day 12. The full
polarization of the two cell lines was also verified by the formation of intercellular tight junction
protein (TJP) (Fig. 4.3).

A

B

Figure 4.1: Cross-section of monolayers of Calu-3 cells (A) and CFBE41o-1 cells (B) growing on
Transwell® insert under ALI conditions.
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Figure 4.2: Transepithelial electrical resistance (TEER) of Calu-3 cells (A) and CFBE41o-1 cells (B)
cultured under ALI (red) or LCC (blue) in 0.33 cm 2 Transwell® inserts as a function of time. Data
represents mean ± SD (n=4).

Figure 4.3: Tight junction protein (ZO-1) staining in Calu-3 cells. Representative CLSM image of fixed
Calu-3 cell monolayer grown at ALI (A) or LCC (B) 10 days post-seeding, and CFBE41o-1 cells
monolayer grown at ALI (C) or LCC (D) 10 days post-seeding. ZO-1 was stained as green. Nucleus (blue)
were counterstained to show the location of cells.

Two P. aeruginosa strains, PAO1 (non-mucoid strain) and FRD1 (mucoid strain), were
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chosen as model pathogens for this co-culture model, as we have established mature in vitro
bacterial biofilm models. After the mammalian cell line formed monolayers, planktonic P.
aeruginosa was inoculated to infect model cells. For Calu-3 cells cultured at LCC, TEER started
to decrease around 4~8 hours after infected with both PAO1 and FRD1 (Fig. 4.4). Interestingly,
when using CFBE41o-1, though a significant TEER drop was observed in the first 2~4 hour post
inoculation, the groups infected with PAO1 were able to maintain and even restore their barrier
property after 8 hours. However, CFBE41o-1 infected with FRD1 did not show the same process;
on the opposite, the barrier property was completed destroyed after 10 hours post inoculation
(Fig. 4.4). Furthermore, we assessed the process of the bacterial colonies forming on the surface
of mammalian cells monolayer as assessed by imaging with confocal microscopy (Fig 4.5 and
Fig. 4.6). For both Calu-3 and CFBE41o-1, floating cells were observed at 8h and the monolayer
started to lose integrity from 12 hours. Some Calu-3 cells were still adherent to substrate after
24h infection, while CFBE41o-1 monolayers were totally destroyed due to the rapid bacterial
biofilm growth (green from bacteria with expression of GFP).

Figure 4.4: TEER reduction of Calu-3 cells and P.aeruginosa (PAO1 and FRD1) co-culture in
Transwell® insert incubated as LCC conditions at a function of time post-infection. TEER reduction of
CFBE41o-1 and P.aeruginosa (PAO1 and FRD1) co-culture in Transwell ® insert incubated at ALI and
LCC conditions as a function of time post-infection. Data represents mean ± SD (n=2).
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Figure 4.5: Confocal image of Calu-3 cells infected with FRD1(A) or PAO1(B) in regular 24 well plate
at LCC conditions.
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Figure 4.6: Confocal image of CFBE41o-1 cells infected with FRD1(A) or PAO1(B) in regular 24 well
plate at LCC conditions.

Although we were not able to develop a stable co-culture model by simply combining P.
aeruginosa and human airway epithelial cells, there are some other strategies that can be applied
to improve the survival time of mammalian cells to establish mature biofilm, and those
corresponds some of the next steps in this area. As bacterial biofilms are usually embedded in
thick mucus, it has been shown that adding mucus from porcine or healthy human being can
elongate the survival time of mammalian cells post infection. We can also potentially inoculate
pre-mature biofilm to mammalian cells monolayer, which saves time for biofilm to grow; such
model has been used to test in vitro drug efficacy.
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As we have demonstrated the in vitro efficacy of our dendrimer-based antibiotics against
biofilm, another interesting future study direction is the establishment of chronic lung bacterial
biofilm on animal models and test in vivo efficacy [259]. As we have observed a trend of
controlled release of our dendrimer-drug conjugates, investigating the potential of dosing interval
will be another interesting next step. Although CFTR knockout mice have been used in the
studies of CF, they typically lack the spontaneous lung infection. Mouse and rate models without
gene knockout have also been widely used specifically to study CF-related lung infections [260].
To mimic chronic infection in CF patients, it is challenging to deliver pathogens to animals’
respiratory tract [261]. Intratracheal inoculation of planktonic bacteria easily results in acute
infection and the death of animal due to the high burden [261]. On the other hand, a relatively
low loading dose of bacteria may not cause death but pathogens can be quickly cleared from the
lung by immune system [261-263]. Thus, embedding bacteria within agar or agarose beads is a
strategy to simulate chronic infection and test the in vivo efficacy of our dendrimer-tobramycin
conjugates. Such animal models can be typically used for a few weeks to test drug efficacy and
pharmacological studies.
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Appendices

Figure S2.1 1H NMR showing successful protection of amine groups (-NH 2) on tobramycin with
Boc group (peak at 1.39 ppm indicating -CH3 of Boc).
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Figure S2.2 MALDI-ToF spectra of tobramycin (Tobra), Boc protected tobramycin (Tobra-Boc)
and succinic acid modified Tobra-Boc (Tobra-Boc-SA).
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Figure S2.3 1H NMR showing successful succination on tobramycin with SA group (peak at
2.50 ppm, -CH2- in succinate, and shift of -CH2- from 3.92-3.40 to 4.30 ppm).
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Figure S2.4 MALDI-ToF spectra of generation 4 polyester dendrimer (G4OH).
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Figure S2.5 MALDI-ToF spectra of G4OH-17NH2. Peak shift from 5370 Da (Figure S2.4) to
7308 Da.
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Figure S2.6 The release profile of dendrimer-tobra conjugates under slightly acidic condition
(pH=6.5) and basic condition (pH=8). The release of tobramycin was roughly assessed by
molecular weight (MW) measurement of partially hydrolyzed G4OH-Tobra from MALDI-TOF
as a function of time.

Figure S2.7 Representative images before and after fluorescence bleach in FRAP assay.
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Pseudomonas aeruginosa (PA) is the predominant pathogen in chronic lung infections of
cystic fibrosis (CF) patients. The most important mechanism of adaptation of PA to host defense
and antibiotic treatment is the formation of biofilms within the mucus layer covering the lung
bronchi. The effectiveness of antibiotics such as aminoglycosides is significantly attenuated by
their limited penetration through thick mucus and embedded biofilm matrix in patients’ lung.
Inhaled tobramycin (Tobra), which is the most commonly used antibiotics in the treatment of PA
infections for CF patients, is usually found to be in very high concentration in patients’ lung, and
yet still cannot prevent CF pulmonary exacerbation.
The purpose of this study was to develop biodegradable dendrimer nanocarriers (DNCs)
with

appropriate

physicochemical

characteristics

that

would

promote

carrier

diffusion/penetration through PA biofilms and pulmonary mucus. We investigated the effect of
surface charge of DNCs on their pentation and diffusion. The positive charge of amine-modified,
fluorescently-tagged (FITC), generation 4 polyester dendrimers (G4OH-(NH 2-FITC)) led to
slower mobility in PA biofilms and model mucus layer compared to their PEG 1000Da-modified
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negatively charged analogs (G4OH-(NH2-FITC)-(PEG)) as measured by fluorescence recovery
after photobleaching (FRAP).

The enhanced penetration of the PEGylated analogs was

attributed to the fact that PEG can act to modulate the interactions between DNCs and the
negatively charged biopolymers in biofilm and mucus matrix upon shielding the surface of the
otherwise positively charged carrier. The effectiveness of Tobra-dendrimer conjugates either
modified with PEG (neutral, G4OH-(Tobra)-(PEG)) and non-PEGylated (positive charge,
G4OH-(Tobra)) was assessed in planktonic and biofilms of non-mucoid (PAO1) and mucoid
(FRD1) PA strains. The minimum inhibitory concentration (MIC) of Tobra hydrolyzed from the
DNCs was of similar magnitude as to free Tobra, indicating that the conjugation and release of
Tobra leads to bioactive drug as the non-released analog and G4OH themselves have MIC >>
then free drug. By contrast, in an established PA biofilm model, PEGylated dendrimer-drug
conjugates demonstrated a significantly stronger bioactivity in eliminating biomass at relatively
higher concentration (8, 16 µg/mL) compared to free Tobra and the positively charged G4OH(Tobra) in mucoid PA strain. Our results demonstrate a correlation between the surface
characteristics of the dendrimer nanocarriers and their ability to efficiently penetrate PA biofilms,
and also that those negatively charged dendrimer nanocarriers can lead to enhanced efficacy in
reducing biofilm in relevant mucoid PA strains. Biodegradable dendrimer nanocarriers with
appropriate design of surface chemistry can thus be a promising approach to overcome the
antibiotic resistance in the treatment of biofilms in CF infections.
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